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INTRODUCTION 
 
Vaginal discharge is considered as a common gynaecological symptom 
which is affecting women of reproductive age group and one of the common 
problem to seek medical attention1. The perception of women to the cause of 
vaginal discharge can influence her choice of treatment. Prior to the consultation 
of her doctor, most of the women would have tried self-treatment using over the 
counter drugs2. This can often lead to unsuccessful outcome. Some women may 
feel embarrassed or have fear in view of sexual transmission as a cause for vaginal 
discharge, which often leads to delay in consultation and treatment3. To overcome 
this problem effectively, it becomes necessary to establish the etiological 
organisms causing vaginal discharge to get appropriate output4. Mixed genital 
infections caused by more than one organism at the same time can compound the 
presentation5. This is particularly true in high risk persons and Human 
Immunodeficiency Virus (HIV) infected patients6. An understanding of this 
association between vaginal discharge and HIV infection is critical for the 
formulation of HIV prevention measures. 
 
Acquired immunodeficiency syndrome (AIDS) is considered as a global 
pandemic with cases virtually reported from all the countries. The main factors 
that have resulted in India’s vast HIV affected population can be due to labour 
migration, low literacy rates in some of the rural population causing lack of 
awareness and disparity.  
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Due to the presence of HIV infection, especially the immunodeficiency of 
AIDS, the clinical presentation of vaginal discharge, its course and complications, 
its response to treatment can be modified resulting in increase in morbidity of the 
patients7. The risk of acquisition and transmission of HIV increases with the 
presence of vaginal discharge8. Screening and treatment of vaginal discharge is 
regarded as an immanent component of health care in those patients infected with 
HIV.  
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
Vaginal discharge is regarded as the commonest presenting complaint 
among sexually active females attending reproductive health clinics. For ages, the 
term vaginal discharge has been used synonymously with leucorrhoea. Vaginal 
discharge can be physiological or pathological. 
 
PHYSIOLOGICAL VAGINAL DISCHARGE 
 Physiological vaginal discharge consists of mixture of transudate through 
mucous membranes, secretions from glandular structures such as sebaceous, 
sweat, Bartholin and Skene glands, and desquamated vaginal epithelial cells. It 
can also be from exfoliated cervical cells, cervical mucus, endometrial and 
fallopian tube fluids, and microorganisms and their metabolic products9. In 
addition to cellular debris, water and electrolytes, facultative microorganisms and 
organic compounds such as fatty acids, proteins and carbohydrates constitute 
vaginal secretion. In case of healthy women, vagina contains 109 bacterial colony-
forming units/gram of secretions10.  
 
The normal vaginal discharge can be thus defined as 
 Clear to white 
 Nonadherent to the vaginal wall 
 Non-malodorous 
 Floccular in consistency 
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 pH of less than 4.5 
 Pooled in the posterior fornix. 
It may result in only minimal staining of the undergarments.  
 
NORMAL VAGINAL FLORA  
 The vaginal flora in a healthy women predominantly consists of 
Lactobacillus species11. Lactobacillus crispatus and Lactobacillus jensenii are 
considered to be the predominant species in the healthy vagina12. Other 
lactobacillus species that are less frequently isolated are, 
 
- L.gasseri 
- L.fermentum 
- L.oris 
- L.reuteri 
- L.vaginalis 
 
The second commonest isolates from healthy vagina are Gram positive cocci. 
These include, 
- coagulase negative staphylococci 
- Beta haemolytic and non-hemolytic streptococci 
- Enterococcus species 
- Peptostreptococcus asaccharolyticus  
- Peptostreptococcus prevotti13 
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 In upto 40% of women, Gram negative rods are also a component of 
healthy vagina, which are found to be Gardenerella vaginalis and Bacteroides 
species. Gram negative cocci, for instance, Veillonella species are infrequently 
isolated from the healthy vagina. Other organisms such as Mycoplasma hominis 
and Ureaplasma urealyticum are common constituents of vaginal flora, yet in 
healthy women both are isolated in small numbers14. Candida albicans is the most 
common yeast isolated from the healthy vagina. 
 
FACTOTS INFLUENCING THE VAGINAL FLORA  
 The type and amount of above secretions can be determined by 
biochemical processes which are influenced by hormone levels.  
 
Age related changes: 
For the first 3 or 4 weeks following delivery, the neonatal vagina is under 
the influence of maternal estrogen. The vaginal epithelium is anatomically and 
physiologically similar to that of the mother and facultative lactobacilli 
predominate15. Thereafter, maternal estrogen is gradually metabolised, the vaginal 
epithelium exfoliates, acid production is lost and the vaginal pH rises. Facultative 
lactobacilli are lost and replaced by skin commensals such as coagulase negative 
staphylococci and fecal organisms such as E.coli. With the onset of puberty, under 
the influence of estrogen, the glycogen content is re-established, lactic acid is 
produced by glycogen metabolism and the healthy vagina is colonised by a 
Lactobacillus dominated flora. At menopause, the vaginal appearance gradually 
reverts to that of pre-menarche status not on estrogen replacement therapy16.  
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Menstrual cycle: 
The greatest species diversity occurred during menses. A transient shifts 
toward an abnormal flora occurred around the time of menses. During menses the 
vaginal pH undergoes temporary elevation but the true reasons for the shifting 
pattern of vaginal flora are poorly understood17. 
 
Pregnancy: 
Women with abnormal vaginal flora in early pregnancy have a tendency to 
revert back to normal as pregnancy progresses. 
 
Contraception: 
Progesterone only contraceptives are found to produce a hypo-estrogenic 
state and a reduction in H2O2 producing Lactobacillus. The use of copper 
intrauterine contraceptive device is strongly associated with the change in the 
vaginal ecosystem to the detriment of facultative lactobacilli18. The effects of 
spermicide nonoxynol-9may adversely affect the lactobacillus population. 
 
Sexual activity: 
The introduction of sperm after sexual intercourse causes a rise in vaginal 
pH, which can take up to 8 hours to return to normal. There is an association 
between the loss of Lactobacillus dominant flora and sexual contact with new and 
multiple male partners. A similar association is found with the exposure to female 
partners.  
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Smoking and genital hygiene practices, such as douching19, have also been 
associated with disruption of the normal vaginal flora. 
 
ABNORMAL VAGINAL DISCHARGE  
Abnormal vaginal discharge is defined as any one of the three presentations  
 Excessive vaginal discharge not associated with menstruation, pre-, mid-, 
and post-period 
 Offensive or malodourous discharge 
 Yellowish or mucopus discharge20 
 
The various causes of abnormal vaginal discharge can be broadly divided into 
 Physiological 
 Age dependent changes: 
 Neonates 
 Pre-puberty 
 Child bearing 
 Due to excessive secretion: 
 Pregnancy 
 Sexual arousal 
                                
 Pathological 
 Under pathological causes, it can be either infective or non-infective. 
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Pathological causes of abnormal vaginal discharge: 
 Infective causes: 
 
Vaginitis: 
 Bacterial vaginosis 
 Vaginal candidiasis 
 Vaginal Trichomoniasis 
 
Cervicitis: 
 Mucopurulent cervicitis due to N. gonorrhoeae and C. trachomatis 
In the prepubertal girl, N. gonorrhoeae causes a vaginal rather than 
cervical infection 
 Herpes genitalis 
 Ectocervicitis due to Trichomonas vaginalis 
 
 Non-infective 
Foreign bodies: 
 Intrauterine contraceptive devices  
 Tampons and other materials 
 
Chemical irritants: 
 Antiseptics 
 Deodarants 
 Bath additives 
 Detergent spermicide 
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 Douches 
 Perfumed soaps 
 
Gynaecological conditions: 
 Endocervical polyp 
 Fistulae 
 Radiation effects 
 Post-operative 
 Tumours 
 Medication and nutrition 
 
BACTERIAL VAGINOSIS 
Bacterial vaginosis (BV) was previously known as 
 Haemophilus vaginalis vaginitis 
 Gardnerella vaginalis vaginitis 
 Anaerobic vaginosis 
 Non-specific vaginosis 
 
 Bacteria vaginosis is the most common form of abnormal vaginal discharge 
in women of reproductive age group21. It is a polymicrobial syndrome 
characterised by a replacement of the normal lactobacillus flora with an 
overgrowth of anaerobic or facultative bacteria associated with a rise in pH above 
4.5.  
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HISTORY 
 Leukorrhea and non-specific vaginitis – It was thought that mixed bacterial 
infections accounted for many unexplained vaginal discharges 
 Gardner and Dukes – In 1955, first described the syndrome as 
“Haemophilus vaginalis vaginitis” and concluded that it was a sexually 
transmitted disease as the isolated agent, H.vaginalis (now renamed 
Gardnerella vaginalis) was found in the male contacts of the female cases. 
 LaPage – In 1961, demonstrated that it had neither X nor V factors, which 
were characteristics of Heaemophilus species. He suggested that it might 
belong to the genus Corynebacterium23. 
 Zinnemann – In 1963, concluded that H.vaginalis was a gram positive 
Corynebacterium, and proposed the term Corynebacterium vaginale. 
 Greenwood – In 1980, suggested the name Gardnerella vaginalis to 
establish a new genus24. 
 
 Bacterial vaginosis is associated with vaginal overgrowth not only of 
anaerobic bacteria, but also by species of facultative bacteria and genital 
mycoplasmas.  
 
EPIDEMIOLOGY 
 Higher rates are found in developing countries than industrialised ones, 
with black women appearing to have double the rates of white. BV is more 
prevalent in women with tubal infertility compared to those with non-tubal 
infertility25. Bacterial vaginosis significantly correlated with increasing years 
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since marriage, lower socio-economic status and parity of more than two, but not 
with age, stage of menstrual cycle and hours since last intercourse. 
 
RISK FACTORS 
 Bacterial vaginosis is regarded as a “sexually enhanced” rather than 
sexually transmitted26, as it can occur in virgin women at a similar prevalence to 
non-virgin women. 
 
Factors positively associated with BV 
 Black ethnicity 
 Smoking 
 Vaginal douching 
 Pessary use27 
 Malodourous gynaecological cancer 
 First intercourse at earliest age 
 New male or female sex partners  
 Greater number of male partners in the last year 
 Low level of education 
 Past history of pregnancy 
 Frequent unprotective sex 
  
 Semen has an alkaline pH, between 7 and 8, and it is estimated that vaginal 
lactobacilli produce enough acid to reduce pH by 0.56-0.75 units/hour28.  
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Thus, frequent unprotected sex may trigger BV through raising the pH. 
 Receptive cunnilingus or anal sex 
 Sexually transmitted infections like Chlamydia, HSV-2, gonorrhoea, PID 
 Lesbian couples29 
 
Factors negatively associated with BV 
 Estrogen 
Estrogen levels alter over the course of a menstrual cycle, being highest in 
the luteal phase when BV is less common 
 Condom usage30 
 
PATHOGENESIS 
The vagina is a dynamic ecosystem that is sterile at birth. Under the 
influence of mother’s estrogen, the glycogen content of vaginal epithelial cells get 
elevated and the infant vagina is colonised by lactobacilli. As the oestrogen 
diminishes, the glycogen also disappears and with it, preconditions for survival of 
lactobacilli. 
 
The vaginal flora of the infant girl is interspersed with contributions of 
coagulase-negative staphylococci, streptococci, E.coli and other intestinal 
bacteria31. This microflora composition continues until menopause. Hormone 
replacement therapy when used will cause lactobacilli to continue as the dominant 
flora.  
 
The vaginal pH in premenarchal females is near neutral (pH 7.0)32. At the 
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time of puberty, under the influence of estrogen, the vaginal epithelium increases 
to about 25 cells thickness with increased glycogen levels, the predominant flora 
changes to lactobacilli and vaginal pH decreases to less than 4.5 due to the 
production of lactic acid. This low pH is maintained until menopause, when 
vaginal pH rises above 6.0. In BV, this symbiotic relation is broken and leads to 
overgrowth of bacteria associated with BV. 
 
Microorganisms implicated in the cause of bacterial vaginosis are31, 
 Gardnerella vaginalis 
 Mobilincus species 
 Prevotella species 
 Mycoplasma hominis 
 Bacteroides ureolyticus 
 Atopobium vaginae 
 Leptrotrichia amnionii 
 Sneathia species 
 Megasphaera species 
 Porphyromonas 
 Peptostreptococcus species 
 Corynebacterium species 
 Streptococcus viridans 
 Coagulase-negative staphylococci 
 Enterococcus faecalis 
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 The bacteria associated with BV produce a number of virulence factors, 
which incluse lipopolysaccharides, sialidases and mucinases33. A haemolytic toxin 
produced by Gardnerella vaginalis cause cleavage of secretory IgA34 and other 
protective factors such as secretory leukocyte protease inhibitor (SLPI). SLPI is 
found in saliva and vaginal fluid and inhibits HIV entry into the cells. Levels were 
significantly reduced in vaginal fluid from women with BV35. The overgrowth of 
anaerobic microorganisms is accompanied by the production of proteolytic 
enzymes that act on vaginal peptides to release several biologic products, 
including polyamines, which volatilize in the accompanying alkaline environment 
to elaborate foul-smelling amines like: 
 Putrescine 
 Cadaverine 
 Trimethylamine36.  
 
 Polyamines act to facilitate the transudation of vaginal fluid and exfoliation 
of epithelial cells, creating a copious discharge. The ratio of succinate produced 
by anaerobic metabolism, to lactate, produced by lactobacilli is increased. These 
microbial substances and virulence factors collectively play a role in overcoming 
cervical host defence barriers leading to the ascent of microbes into the upper 
reproductive tract. They collectively cleave mucus leading to the thin 
homogenous discharge that is characteristic of BV. 
 
Synergistic relations between different BV associated organisms have been 
demonstrated. The stimulation of Gardenerella vaginalis growth has been 
15 
 
 
observed with the production of amino acids by anaerobes and ammonia by 
Prevotella bivia.  
 
CLINICAL FEATURES  
 Unpleasant fishy smell. The smell is more obvious after unprotected sexual 
intercourse or with menstruation when elevated pH makes the amines more 
volatile. 
 Non-viscous thin homogenous discharge, that smoothly coats the vaginal 
walls, often visible on the labia and fourchette37. 
 Pruritus 
 Pain during coitus 
 Lower abdominal pain 
 Burning micturition  
 
DIAGNOSIS 
The presenting symptoms alone are not reliable for the diagnosis of BV. It 
can co-exist with other common causes of abnormal discharge. Diagnostic criteria 
established by Amsel have proved remarkably simple and useful in clinical 
practice. 
 
Amsel's Diagnostic Criteria for Bacterial Vaginosis38: 
 Three of the four criteria must be met, which establishes accurate diagnosis 
of bacterial vaginosis in 90 percent of affected women.  
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 Homogeneous vaginal discharge  
The discharge should be thin, homogenous and uniformly adherent to the 
vaginal walls. It must not have any granular material. 
 
 Whiff test 
The odour of the secretions should be tested by smelling the withdrawn 
speculum39. Norma vaginal secretions do not have an unpleasant odour. If 
this is negative, a more sensitive procedure for detecting amines is by 
adding a few drops of 10% Potassium hydroxide to a few drops of vaginal 
secretions and immediate smelling of the specimen for the transient “dead 
fish”odour that is characteristic of BV. Weakly positive whiff test may be 
produced by menstrual blood and semen.  
 
 Vaginal pH greater than 4.5 
The pH of vaginal secretions should be determined by using a strip of 
narrow range pH paper, which may be applied to the withdrawn speculum 
or directly inserted into the vagina. It is unusual for BV to have a pH more 
than 5.540. 
 
 Presence of clue cells (greater than 20%)  
Wet mount and Gram’s stain of vaginal secretions should be done to look 
for clue cells. Detection of clue cells is the most useful single procedure for 
diagnosis. 
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Clue cells, first described by Gardner as giving “a clue to the diagnosis,” 
are epithelial cells coated with a thick film of small bacteria such that the border is 
obscured41. The presence of clue cells is the most specific sign, but the specificity 
increased by using a cut-off of atleast 20% epithelial cells being clue cells42. 
 
Gram staining of the smear has been shown to be a simple inexpensive, 
sensitive, specific and reproducible way to diagnose BV. Spiegel defined criteria 
that made it easy to diagnose BV by scoring Gram-stained vaginal secretion 
smears. 
 
Nugent Scoring43 was established by Nugent et al. A new scoring system 
that uses the most reliable morphotypes from the vaginal smear was proposed for 
diagnosing bacterial vaginosis. 
 
Nugent Scoring System for Gram-stained Vaginal Smears: 
Score Lactobacillus morphotypes 
 
 
 
 
 
+ 
Gardnerella and 
bacteroides 
morphotypes 
 
 
 
 
 
+ 
Curved Gram- 
variable rods 
0 4+ 0 0 
1 3+ 1+ 1+ or 2+ 
2 2+ 2+ 3+ or 4+ 
3 1+ 3+ - 
4 0 4+ - 
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A score between 0 and 10 is derived from the weighted combination of the 
following:  
 Large Gram positive rods (lactobacilli) 
 Small Gram negative or variable rods (Prevotella species or G.vaginalis) 
 Curved Gram negative or variable rods (Mobiluncus species) 
 
Each group is quantitatively weighed on a scale of 0 to 4: 
 0 = no morphotype per oil field 
 1+ = less than one morphotype per oil field 
 2+ = one to four morphotype per oil field 
 3+ = five to 30 morphotype per oil field 
 4+ = more than 30 morphotype per oil field 
 
 Plentiful lactobacillus morphotypes are considered normal, therefore the 
score is inversely related to the number of organisms, 4+ lactobacillus scores 0, 
3+ scores 1 and so on. For Gardnerella, Gardnerella gives a score of 4 and so on. 
Mobiluncus is similarly correlated but weighed lower, so 1+ and 2+ organisms 
scores 1 and 3+ and 4+ score 2. Therefore a Gram stain with “severe BV” scores 
10 (4 for absence of lactobacillus morphotypes, 4 for 4+ Gardnerella morphotypes 
and 2 for 4+ Mobiluncus morphotypes).  
 
 A normal Gram stain scores 0(0 for lactobacillus morphotypes, 0 for 0 
Gardnerella morphotypes and 0 for 0 Mobiluncus morphotypes). 
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 A total score of 7 to 10 (the sum of rating score of those three groups) is 
considered to be indicative of BV, a score of 4 to 6 intermediate flora, and 0 to 4 
normal flora. The limitation of Nugent scoring is, requirement of a skilled 
operator and can be time consuming. 
 
 The Hay-Ison system is another scoring system based on the observation of 
gram stains to estimate the ratios of the observed morphotypes rather than the 
exact number of bacteria44.  
 
 Grade I (normal flora), lactobacillus morphotype only or predominate 
 Grade II (intermediate flora), reduced lactobacillus morphotype with mixed 
bacterial morphotypes 
 Grade III (BV), mixed bacterial morphotypes with few or absent 
lactobacillus morphotypes. 
 
Two additional grades are used also; 
 Grade 0, epithelial cells with no bacteria seen 
 Grade IV, epithelial cells covered with Gram positive cocci such as 
Streptococcus or Staphylococcus morphotypes only 
 
 Schmidt’s scoring system of wet smears of vaginal fluid (wet smear 
criteria) resembles Nugent scoring in that it ranks the quantities of lactobacilli and 
cocci in the same way, although the demarcation of the intervals differ45. 
Schmidt’s scoring system does not recognize Mobiluncus. The Schmidt method 
has been validated for diagnosis of BV in primary care populations. 
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 Detection of biochemical changes in vaginal fluid is an alternative way of 
making the diagnosis but not often used routinely. Gas-liquid chromatography, 
used for identification of fatty acids is useful as a research tool32.  A ratio of the 
succinate to lactate peaks of more than 0.4 is highly predictive of BV. Elevated 
levels of acetate, propionate, isobutyrate or isovalerate can also be used for 
detection of BV.  
 
 Affirm VPIII uses DNA hybridization to detect high levels of 
Gardnerella46. Another test is FemExam. FemExam card 1 has indicators for pH 
greater than or equal to 4.7 and one for amines greater than 0.5 mmol, card 2 
measures proline imminopeptidase activity47. Several other alternative methods 
have also been used to develop easy, inexpensive and reproducible diagnostic 
methods such as rapid nucleic acid hybridization test. 
 
HIV AND BACTERIAL VAGINOSIS 
 An understanding is now emerging of how BV could enhance the 
susceptibility to HIV infection48. The normal vagina is colonised by Lactobacillus 
species and are found to defend against infection caused by other species. The 
efficacious mechanisms for this defence have been identified as:  
 
1) Direct competition for nutrients 
2) Blocking the adhesion of other microbes to epithelial cell receptors 
3) Secretion of defensins and bacteriocins, which can disable the growth of 
bacterial pathogens49 
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4) Production of lactic acid, which helps in maintaining the low vaginal pH, 
produces acidic vaginal environment, inhibiting the growth of other micro-
organisms, including those species causing Bacterial vaginosis50.   
5) Lactobacillus dominant flora have H2O2 producing lactobacilli. 
 
 L.crispatus and L.jensenii appear to be more protective against BV 
emerging than L.gasseri. H2O2 produced by these strains of lactobacilli is 
inhibitory for certain bacteria in the vagina, particularly catalase-negative bacteria 
that do not have the enzyme that detoxifies H2O2.  H2O2 may inhibit the growth of 
bacteria either directly via the toxic activity of H2O2 or by reacting with halide ion 
in the presence of cervical peroxidise as part of H2O2-halide-peroxidase 
antibacterial system. These inhibit not only bacteria, but also HIV and other 
viruses. 
 
 BV is characterised by the absence of lactobacilli and thus elevated pH. A 
low vaginal pH may inhibit CD4 lymphocyte activation and therefore decrease 
HIV target cells in the vagina; Conversely, an elevated pH may make the vagina 
more conducive to HIV survival and adherence. 
 
 BV has been shown to increase the intravaginal levels of pro inflammatory 
cytokines, IL-1β and IL-851. IL-1β can excite the secretion of other pro-
inflammatory cytokines. IL-8 can increase the number of cellular targets for HIV 
by recruiting the immune cells52. BV also increases the levels of interleukin 10, 
which increases the susceptibility of macrophages to HIV. 
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 In addition, the mucin degrading enzymes in BV will make it easier for 
HIV to infect by breaking down the cervico-vaginal mucosa. It has also been 
hypothesized that the level of acidity within the vagina may affect CD4 
lymphocyte activation. The more alkaline the environment, the more likely it is 
that CD4 lymphocytes will be activated and thus act as suitable target cells for 
HIV. 
 
COMPLICATIONS 
 The symptoms of BV can be distressing for those with frequent 
recurrences. It can adversely affect sexual and family relationships and working 
lives, and lead to depression.  
 
 Acquisition of sexually transmitted infections, including HIV, HSV, 
Gonorrhoea, Chlamydia. 
 Urinary tract infections 
 Urinary tract infections in women is linked to persistence of E.coli in the 
vagina. Since lactobacilli inhibit E.coli, BV is associated with increased 
rate of Urinary tract infections. 
 Upper genital tract infections- spontaneous PID and Post-abortal 
endometritis. 
 Post hysterectomy vaginal cuff cellulitis (occurs when vaginal bacteria 
contaminate the operative field during a hysterectomy) 
 Chorioamnionitis during pregnancy 
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 Leads to pre-term delivery and pre mature rupture of membranes. The 
release of inflammatory mediators including IL-1, IL-6 and TNF-alpha stimulate 
the production prostaglandins, the final pathway for initiating labor. The 
cytokines, endotoxins, exotoxins also initiate neutrophil chemotaxis, infiltration 
and activation, leading to rupture and they also soften the cervix53. 
 Second trimester miscarriage 
 Spontaneous pre-term birth, pre mature rupture of membranes, low birth 
weight. 
 Reduced chance of successful IVF 
 
 Endometritis associated with BV, is likely to be unfavourable for 
implantation. In women undergoing IVF, isolating bacteria associated with BV 
results in poorer outcome. 
 Post caesarean section endometritis 
 
RECURRENT BACTERIAL VAGINOSIS 
Recurrent BV is defined as 4 or more appearances of infection in one 
year54. When BV recurs, it is most likely to be a reactivation rather than a 
reinfection. Options for treatment of recurrent BV includes, retreatment with 
metronidazole or clindamycin and local therapy with clotrimazole. Other 
modalities include supplement of H2O2, vaccination with lyophilized 
lactobacillus acidophilus and intravaginal Lactobacillus capsules.  
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TREATMENT  
The treatment of bacterial vaginosis as recommended by CDC is as follows: 
 Metronidazole 500 mg orally twice a day for 7 days 
 0.75% Metronidazole gel, one full applicator (5g) intravaginally, once a 
day for 5 days 
 Clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime 
for 7 days 
 
Alternative regimens: 
 Tinidazole 2 gm orally once daily for 2 days 
 Tinidazole 1gm orally once daily for 5 days 
 Clindamycin 300 mg orally twice a day for 7 days 
 Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days 
 
In Pregnancy: 
All symptomatic pregnant women should be tested and treated. 
 Metronidazole 500 mg orally twice a day for 7 days 
 Metronidazole 250 mg orally thrice a day for 7 days 
 Clindamycin 300 mg orally twice a day for 7 days 
 
Metronidazole is not recommended for use in the first trimester of pregnancy, 
where topical treatment can be used. 
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TRICHOMONAS VAGINALIS 
Trichomonas vaginalis (TV) infection is considered as a most prevalent 
non-viral sexually transmitted disease occurring in adolescents54. Trichomonas 
vaginalis is a sexually transmitted protozoan parasite that invades genital epithelia 
and may cause trichomoniasis in women and urethritis in men. 
 
HISTORY 
 It was first reported as a venereal infection in the mid-20th century, which 
was even before the recognition of Chlamydia trachomatis infection. 
 Kunstle – In 1833, described the behaviour of trichomonas parasite within 
the female urinary tract. 
 Marchand – In 1834, identified the organism in male urinary tract 
 Alfred Donne – In 1836, first described the species from a freshly made 
unstained wet mount preparation of vaginal discharge smear mixed with 
saline. It was first recognised as causing the disease in 191655. 
 
EPIDEMIOLOGY 
Trichomonas vaginalis, a parasitic protozoa that causes the sexually 
transmitted infection trichomoniasis, is a sexually transmitted infection with the 
largest annual incidence, exceeding to170 million cases per year56. 
 
Human beings are regarded as the optimal hosts, where trichomonas are 
transmitted exclusively through sexual intercourse. Transmission through 
contaminated fomites can also occur, as T.vaginalis survives upto 45 minutes on 
toilet seats, wash clothes and bath water57. Trichomonas vaginalis infection 
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affects the genitourinary tract of sexually active women of all age groups and acts 
as a source of sexually transmitted infection. In women, the symptoms can range 
from severe irritation and inflammation producing frothy vaginal discharge to an 
asymptomatic carrier state58. Asymptomatic infection is widely considered to be a 
nuisance rather than a threat to reproductive health. It occurs more common in 
women than men. 
 
BIOLOGY 
 Trichomoniasis is caused by Trichomonas vaginalis, a protozoan belonging 
to the order trichomonads. Three species are found in humans: 
 Trichomonas vaginalis 
 Trichomonas tenax 
 Pentatrichomonas hominis 
 
 T.tenax and Pentatrichomonas hominis are non-pathogenic ttrichomonads 
that are found in the oral cavity and large intestine respectively. Trichomonas 
vaginalis is a flagellated protozoan that is highly motile. Trichomads, which are 
approximately the size of lymphocytes, 15-25 micrometer in length. It has 
characteristic erratic or twitching motility. It has four anterior flagella that 
originate from the anterior kinetosomal complex, and fifth flagellum attached to 
the undulating membrane that arise from the kinetosomal complex and extends till 
half the length of the organism. Other components are anterior nucleus with 5 
chromosomes, golgi complex, parabasal apparatus and axostyle which run along 
to form the tail or projection posteriorly55.  
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 Three rows of larger chromatin granules are arranged parellel to the 
axostyle which hydrogenosomes. Reproduction is by mitotic division and 
longitudinal fission, which occurs every 8-12 hours under optimal conditions.  
 
Figure 1: Structure of Trichomonas Vaginalis 
 
 They are present in two forms. The smaller form which is more virulent 
and the largest form which is more dormant. The later are formed in 
asymptomatic infections, while the former in symptomatic disease. T.vaginalis is 
strictly anaerobic and can survive in a variety of pH conditions ranging from the 
highly acidic (pH 3.5), which is common during bacterial vaginosis, to basic(pH 
8.0). As a result of sensitivity to atmospheric oxygen, drying conditions and 
temperature below 35 degree celsius, T.vaginalis does not survive ex vivo for 
extended periods (greater than a few hours).  
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Organisms lose its motility quickly at room temperature. 
RISK FACTORS59  
 Higher number of sexual partners 
 Inconsistent condom use 
 Sex in exchange for money or drugs 
 Intravenous drug abuse 
 Previous infection with T.vaginalis 
 Lower socio-economic status 
 Residence in correctional facility 
 Co-infection with other STIs 
 History of delinquency 
 
PATHOGENESIS 
Upon entry into the vaginal milieu, T. vaginals encounters the mucous 
layer that is the first line of defense from microbial colonization. Trichomonads 
produce enzymes that degrade mucin, the major component of mucous, thus 
allowing the organisms to come into contact with the cells of vaginal epithelium. 
Trichomonads also produces adhesins that enable attachment of the pathogen in 
the cell surface of vaginal epithelium. These adhesins are upregulated during 
times of high iron concentration. This mechanism may allow trichomonads to 
remain adhered to cells during menses60. Contact with epithelial cells result in 
their destruction and recruitment of inflammatory cells to the vagina, resulting in 
vaginal discharge. Cyto-adherence, which ultimately leads to cytotoxicity, is a 
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dynamic and complex process involving a cascade of reactions may be 
responsible for T.vaginalis infection. As a result, infection can cause a range of 
outcomes from completely asymptomatic disease to symptomatic with heavy 
discharge, odor, and itching. Trichomanads themselves are susceptible to infection 
by a double stranded RNA virus that may influence the virulence of 
trichomonas61. Virus infected trichomads may have a survival advantage when in 
humans. These are less likely to be resistant to metronidazole. Molecular mimicry 
of one of the adhesion molecules with malic enzyme could be responsible for 
evasion of host immune defences by the parasite.  
 
CLINICAL FEATURES  
The incubation period for T.vaginalis infection has been reported to be 
between 4-28 days. About 50% of women are asymptomatic, but 30% of them 
will develop symptoms when observed for 6 months.  
 
Asymptomatic carriers are important reservoir of infection. Symptoms occur 
in women with high organism load. Women may experience, 
 Vaginal discharge 
 Vaginal itching 
 Musty odor 
 Dysuria 
 Pelvic pain 
 Irregular bleeding 
 Pain or bleeding on coitus 
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 Vaginal secretions were usually copious, homogenous, malodorous with 
pH of 4.5 and yellow-green or grayish colour. Punctate mucosal haemorrhages 
with ulcerations over the cervix are referred as, 
 Colpitis macularis62 
 Strawberry cervix 
 Flea-bitten cervix 
 
 The positivity of this finding on naked eye examination is only 2.5% as 
compared to 52% on colposcopy. It was observed that vaginal fluid from women 
with colpitis macularis have more number of T.vaginalis protozoa compared to 
women without colpitis macularis55. The organism are isolated from vagina, 
cervix, urethra, bladder, Bartholin glands and Skene glands in females. 
 
DIAGNOSIS 
Direct Microscopic Examination:  
Making a wet mount of vaginal discharge and examination of urine in 
males can be used in making the diagnosis. Wet preparations are prepared by 
suspension of vaginal or urethral fluids in normal saline. The suspension is placed 
over the slide and examined for motile trichomonads. This technique remains the 
most frequently used diagnostic method even in technologically advanced 
settings. Various staining methods have been described, like use of acridine 
orange, Giemsa, fluorescein and periodic acid-schiff to improve the sensitivity of 
microscopic evaluations. Other stains include Papanicolaou, neutral red and 
peroxidise stains. Routine Papanicolaou stained smears detected T.vaginalis on 
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cytological examination in asymptomatic women63. Direct fluorescent antibody 
technique is rapid, easy to perform, and relatively inexpensive as compared to 
culture. 
 
Culture:  
Culture for detection of T.vaginalis was considered the gold standard of 
diagnosis. It is especially of use when the organism load is low (asymptomatic 
women). Culture allows replication of organisms, thus increasing the probability 
of detection of motile organisms using microscopy. The inoculum size required is 
only in the range of 102 organisms/ml and the growth of the organism is easy to 
interpret. 
 
Various media have been used to detect trichomonas55, such as, 
 Diamond media (tripticase, yeast and maltose) 
 Modified Diamond media (yeast extract and supplemented with inactivated 
horse serum, amphotericin B, penicillin G and gentamicin) 
 Kupfurberg media 
 Lash media 
 Feinberg-Whettington media 
 
 Swabs containing vaginal secretions are inoculated into tubes containing 
medium and incubated for upto 5 days at 35-37 degree celsius. The yield on 
culture usually takes 3-7 days. T.vaginalis is an anaerobic organism that grows 
more slowly under aerobic conditions. Thus CO2 is recommended for optimal 
recovery64. 
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 The disadvantage of culture techniques are the delay in diagnosis, 
unavailability of culture media, more expensive and death of organism in transit. 
To improve the acceptability of culture for diagnosis, a two chambered plastic bag 
culture system called InPouch TV was developed, which allows direct 
inoculation, transport and culture. This allows microscopic evaluation of the entire 
culture rather than a single drop, thus improving the sensitivity and results are 
obtained earlier than the routine culture65.  
 
 Cultivation on cell cultures is more sensitive, enabling the observation of 
T.vaginalis from an inoculum containing as few as 3 organism/ml. This method is 
expensive, inconvenient and prone to vaginal bacterial contamination. 
 
Immunological methods: 
 A variety of serological assays are used to determine the presence of 
trichomonal antibodies66. 
 Complement fixation 
 Hemagglutination 
 Gel diffusion  
 Fluorescent antibody 
 ELISA 
 
 Other detection methods used are antigen detection technique using 
monoclonal antibody against T.vaginalis in vaginal secretions.  
 
 The most sensitive diagnostic methods for diagnosing trichomonal 
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infections are nucleic acid amplification tests (NAAT)67. These tests are based on 
enzymatic amplification of DNA or RNA to produce an exponential increase in 
the concentration of organism-specific targets. A commercially available DNA-
based test called the Affirm VP system, which uses synthetic oligonucleotide 
ptobes for detection of T.vaginalis, Gardnerella vaginalis, Candida species from a 
single vaginal swab.  
 
HIV AND TRICHOMONAS VAGINALIS 
 Infection with Trichomonas vaginalis can deteriorate the mechanical 
barrier by means of punctate mucosal hemorrhages, resulting in entry of 
HIV at ease.  
 TV infection predisposes the vaginal epithelium to procure bacterial 
vaginosis by altering the normal vaginal flora, which successively 
increases the risk of acquiring HIV. 
 TV infection increases vaginal shedding of HIV as a result of local 
inflammation, among HIV infected women68. 
 Symptomatic inflammatory trichomoniasis may increase HIV excretion in 
semen, thereby increasing HIV acquisition in women.  
 Repeated infections, re-infection with a different strain and resistant cases 
of Trichomonas were common in women infected with HIV. Hence forth, 
it is crucial to do a HIV testing when there is evidence of Trichomonas 
infection. 
34 
 
 
 Trichomonads attach easily to mucous membrane and may also serve as 
vectors for the spread of other organisms, carrying pathogens attached to 
their surface into upper genital tract, which in turn leads to co-infection and 
increasing the risk of HIV acquisition  
 It is observed that, HIV shedding can be significantly reduced from the 
vaginal mucosa by treating Trichomonas infection 
 
 By identifying and treating the trichomonas infection, it is possible to 
reduce the acquisition and also transmission of fatal HIV infection69. 
 
COMPLICATIONS 
 low birth weight 
 risk of tubal infertility 
 preterm delivery 
 pelvic inflammatory disease 
 premature rupture of membranes 
 risk of post hysterectomy infection 
 post abortal infection 
 risk factor for cervical neoplasia 
 
TREATMENT 
 Trichomonas infects squamous, but not columnar, epithelium. The urethra 
and Skene's glands are often involved, explaining the need for systemic rather 
than local therapy. Recommended regimen by CDC, 
  
35 
 
 
 
 Metronidazole 2 g orally in a single dose 
 Tinidazole 2 g orally in a single dose 
 
Alternative regimen: 
 Metronidazole 500 mg twice a day for 7 days 
 
 The nitroimidazoles comprise the only class of drugs useful for the oral or 
parenteral therapy of trichomoniasis. Treatment of patients and sex partners 
results in relief of symptoms, microbiological cure and reduction of transmission. 
 
 If the treatment failure occurs with metronidazole 2 g single dose and 
reinfection is excluded, the patient can be treated with metronidazole 500 mg 
orally twice daily for 7 days or tinidazole 2 g single dose. For patients failing 
either of these regimens, clinicians should consider treatment with tinidazole or 
metronidazole at 2 g orally for 5 days. 
 
In pregnancy:  
Pregnant women can be treated with the same treatment regimen. 
Metronidazole is pregnancy category B drug. In lactating women who are 
administered metronidazole, withholding breastfeeding during treatment and for 
12-24 hours after the last dose will reduce the exposure of metronidazole to the 
infant. While using tinidazole, interruption of lactation is recommended during 
treatment and for 3 days after the last dose. Tinidazole in pregnancy is category C 
drug. 
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Resistance:  
The CDC estimates that 2.5% to 5% of T.vaginalis isolates display some 
level of resistance to metronidazole70. The mechanism of resistance to 
metronidazole also controlled by hydrogenosomes, in that metronidazole 
competes for H+ as an electron acceptor. In metronidazole resistant T.vaginalis , 
the expression levels of the hydrogenosomal enzymes pyruvate ferrodoxin 
oxidoreductase, ferridoxin, malic enzyme and hydrogenase are reduced 
dramatically, which probably eliminates the ability of the parasite to activate 
metronidazole. 
 
Tinidazole is a second generation nitroimidazole with activity against 
protozoa and anaerobic bacteria, which is found to be effective in metronidazole 
resistant cases. Tinidazole has a plasma elimination half-life twice that of 
metronidazole (12-14 hours vs 6-7 hours) and penetrates better into male 
reproductive tissues than metronidazole. Tinidazole have demonstrated lower 
incidence and severity of side effects compared with metronidazole. 
 
CANDIDAL VULVOVAGINITIS 
 Vulvovaginal Candidiasis (VVC) is the most common cause of vaginitis in 
the tropics. It is known by several other names, 
 candidosis 
 moniliasis 
 thrush 
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HISTORY 
 1849 – Vaginal candidiasis was first described 
 1853 – The pathogen was named as Oidium albicans71 
 1954 – The name was derived from the word Candida describing the white 
robe (toga) worn by Roman Senators and this name was adopted 
internationally. 
 1920 – Candidal balanitis was first reported 
 
EPIDEMIOLOGY  
Vulvovaginal candidiasis (VVC) affects 75% of sexually active women 
with atleast one lifetime episode and 40-50% suffering a recurrence. About 5%–
8% of women will experience multiple episodes each year72.  
 
Candida species are found in humans, animals and many food stuffs 
particularly fruit juices. In humans, Candida species are found in the oropharynx, 
rest of the gastrointestinal tract and from there they colonize to the vulvovaginal 
area. It peaks in incidence at 20-40 years of age and is found in postmenopausal 
women who are on estrogen supplements.  
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BIOLOGY  
Candida vaginitis is most commonly caused by Candida albicans. Other 
species in order of incidence include, 
 Candida glabrata 
 Candida tropicalis 
 Candida parapsilosis 
 Candida krusei 
 Candida guiliermondii 
 Candida kefi 
 
 Candida, classified as yeast, is a dimorphic fungi that forms budding 
blastoconidia, which elongate into pseudohyphae and these can develop into true 
hyphae. Candida is in the class of blastomycetes but under the order 
Cryptococcales. The species differentiation can be done by colony characteristics, 
microscopy, biochemical reactions such as fermentation, assimilation of sugars 
and growth in different nutrient media. The germ tube test where the yeast 
produces hyphal germ tubes when incubated at 37°C in serum for 2-3 hours is the 
classic diagnostic test. Chlamydospore formation on cornmeal polysorbate 80 agar 
at 22°C to 25°C in 48-72 hours confirms the identity73. Candida transmission 
probably occurs through its yeast form that is present in asymptomatic infection. 
The pseudomycelial form is associated with invasion and symptomatic infection. 
The yeast develops into a hypha with the expression of virulence genes that can 
encode hyphal wall protein; cyclic adenosine monophosphate plays a role through 
C.albicans cyclase associated protein gene. Switching may also enhance adhesion 
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and secretion of pathogenic enzymes such as phopholipases, aspartate 
transaminases and other proteinases. 
 
HOST DEFENSE MECHANISMS 
Humoral immunity: 
Humoral immunity does have some part to play in the initial local 
defences. High levels of IgA can be found in infected patients, but they do not 
prevent colonization.  Women with elevated IgE show an increased amount of 
prostaglandin E2 in vaginal secretions, which is known to enhance C.albicans 
germ tube formation and reduce peripheral blood lymphocyte production. 
Macrophages and lymphocytes are important in protection against systemic 
invasive candidiasis. 
 
Cell mediated immunity: 
Cell mediated immunity is the most important host defense mechanism 
against mucosal candidiasis. Th1 and Th2 responses cross regulate each other, and 
if there is enough increase in antigenic load, there may be an induction of Th2 
type response. This could inhibit the normal protection associated with the Th1-
type reactivity. 
 
RISK FACTORS  
 Diabetes mellitus 
 Immunosuppression from HIV 
 Broad spectrum antibiotic therapy 
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 Estrogen: Estrogens are associated with cyclical candidiasis (pre-period). 
Candidiasis is associated with hormone replacement therapy and also with 
pregnancy, particularly in the third trimester. Estrogen increases the 
glycogen in epithelial cells, which is a carbon source for yeasts. It also 
increases adherence of Candida to the epithelial cells and enhances yeast 
mycelium formation. Progesterone contraceptives and lactation are 
probably protective. 
 Douching 
 Tamoxifen treatment in post-menopausal women 
 Increased moisture, occlusion: This is associated with use of non-cotton, 
tight fitting clothes in the tropics. 
 Atopy: Associated with Recurrent Vulvo Vaginal Candidiasis74 
 Vitamin A deficiency: Affects keratinization and host defenses 
 Zinc deficiency  
 Use of steroids: interferes with polymorph phagocytosis 
 
PATHOGENESIS 
Adherence: 
Candida albicans has the greatest affinity for adhering to vaginal epithelial 
cells, followed by C.tropicalis and C.parapsilosis. Adherence is dependent on 
many factors, which include competing for cellular binding sites; nutrients such as 
glucose, the concentration of hormones, particularly estrogen, which increases the 
avidity of epithelial cells for C.albicans, and the presence of immunoglobulin A 
which interfere with adherence75. 
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Cell surface hydrophobicity of C.albicans is important in adherence. Germ 
tube formation is associated with a significant rise in Cell surface hydrophobicity. 
Initial adherence is dependent on unidentified receptors, adhesions related to 
fibronectin. The mannoprotein component on the yeast surface probably plays a 
role and is associated with impaired phagocytosis. Adherence leads to 
colonization and increased population density is associated with symptomatic and 
invasive disease.  
 
Invasion: 
Proteinases breakdown peptide bonds, phospholipases enhance invasion, 
carboxyl phospholipses are proteolytic to keratinocytes, and aspartate proteinases 
are collagenolytic.  
 
CLASSIFICATION OF VVC 
Uncomplicated Complicated 
 
 Sporadic or infrequent VVC 
 Mild to moderate VVC 
 Candida albicans 
 Non-immunocompromised 
women 
 
 Recurrent VVC 
 Severe VVC 
 Non Candida albicans candidiasis 
 Women with uncontrolled 
diabetes, immunosuppression, 
debilitation, pregnancy 
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CLINICAL FEATURES 
Uncomplicated VVC: 
a. Swelling and redness of vulva with fissuring 
b. Itching – worse at night or after a shower 
c. White curdy discharge 
d. Dyspareunia 
 
 Vulva may be edematous with visible adherent white discharge at the 
introitus and vestibular area. External vulva shows evidence of fissuring. 
Speculum examination shows inflamed vaginal epithelium with white plaques like 
‘cottage cheese’ may be seen. 
 
Complicated VVC: 
Recurrent VVC is defined as 4 or more episodes of symptomatic VVC per 
year. 
 
 There may be rash with satellite micropustules around the outer labia and 
redness and involvement of the perianal region. Women with post-thrush 
vestibulitis may have tender areas around hymenal ring. There may be increased 
redness and increased vascularity around the areas of vestibulitis. 
 
DIAGNOSIS 
pH measurement: 
The pH of the vaginal discharge is usually low between 3 and 4.5, which 
distinguishes it from other causes of vaginitis. Swabs should be taken from the 
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lateral vaginal wall and placed on the pH paper. Contamination with blood, 
cervical mucus, semen and local medications like anti-fungal creams should be 
avoided as it may affect the pH of the secretions. 
 
Microscopic examination: 
Wet mount of saline preparation is done to exclude clue cells and 
trichomonads. A sample of vaginal secretion is taken with a loop and mixed with 
a drop of saline on one slide and drop of 10% KOH on another, cover slips placed 
on top and viewed under low power microscopy. Budding yeasts and lengths of 
pseudohyphae may be seen. 
 
Culture: 
Swabs from the lateral wall of the vagina can be placed in Amies medium 
or can be directly plated on a Sabouraud plate. New Chromogenic agar media76 is 
used for the differentiation of candida species are useful when mixed infections 
are suspected.  
 C.albicans : green colonies 
 C. krusei : flat pink 
 C.tropicalis : blue colonies 
 C. glabrata : pale pink 
 
Others: 
 Polymerase chain reaction 
 Latex agglutination slide technique 
 Pap smear 
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HIV AND CANDIDIASIS 
Oropharyngeal candidiasis presents earlier in HIV-seropositive patients 
with higher CD4+ cell count compared to those with VVC. The first report of 
Vulvovaginal Candidiasis in HIV-positive women was appeared in 1987. VVC in 
HIV-infected women are more frequent and chronic. They are also more 
persistent and response to anti-fungal therapy is poor77. History of previous 
symptomatic Candida vaginitis, pregnancy and diabetes are the predictors of 
positive colonisation among HIV-seropositive patients78. 
 HIV infected women shows higher rates of vaginal candida colonization 
than HIV uninfected women of comparable demographic and risk 
behaviour characteristics. 
 Low CD4 counts and increased viral load correlate with highest 
colonization rates. The cause of the enhanced colonization is related to loss 
of immunoprotective mechanisms seen in the vagina. Colonization is 
important because when suitable risk factors and contributing factors are 
present, it predisposes to further transformation of asymptomatic form to 
symptomatic Candida vaginitis.  
 Mixed vaginal infections, comprising of more than one species of candida 
occur rarely in sero-negative women. On the contrary, in HIV positive 
women, there observed a rise of co-colonization with two species of 
candida79. 
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COMPLICATIONS 
In pregnancy:  Premature rupture of membranes 
                         Preterm labour 
                         Chorioamnionitis 
                         Congenital cutaneous candidiasis 
 
TREATMENT  
Uncomplicated VVC: 
Short course topical formulations are effective in treating uncomplicated 
VVC. Local imidazole treatments in the form of ovules, pesseries, tablets and 
creams have relatively equal efficacy. Systemic therapy such as single dose of 
oral fluconazole 150 mg can help in moderate cases. 
 
Complicated VVC: 
Predisposing factors like diabetes mellitus and HIV should be treated. 
VVC can occur concomitantly with other STDs and the latter has to be 
investigated and treated.  
 
Induction therapy: 
 Oral Fluconazole 150 mg (day 1,4,7) 
 Topical anti-fungals for 7-14 days 
 
 Induction therapy should be given to achieve mycological remission before 
starting on maintanence therapy. 
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Maintanence therapy: 
 Clotrimazole 150 mg vaginal suppository, once weekly (or) 
 Ketoconazole 100mg once daily (or) 
 Fluconazole 100-150 mg once weekly (or) 
 Itraconazole 400 mg, once monthly  
 
All maintanence regimen should be continued for 6 months. 
Non albicans VVC: 
Long duration of therapy with non fluconazole regimen can be considered 
as a first line therapy. 
 
Other considerations are, 
 Intravaginal boric acid 600mg/day for 14 days 
 Intravaginal 17% Flucytosine  
 
Pregnancy: 
 The oral imidazoles are contraindicated in pregnancy because of 
teratogenicity from the long term use of high dose of fluconazole.  
 Extended course of topical azoles for 10-14 days 
 Clotrimazole vaginal pesseries, 500 mg intravaginally every one or two 
weeks 
 
SYNDROMIC MANAGEMENT FOR VAGINAL DISCHARGE 
 Oral Fluconazole 150 mg single dose and oral Secnidazole 2 gm single 
dose (green kit) 
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CERVICITIS CAUSING ABNORMAL VAGINAL DISCHARGE 
GONORRHEA 
The word gonorrhoea is derived from combination of Gonos, 'seed’ and 
rhoea, ‘flow'. It was considered that gonorrhoea and syphilis are caused by the 
same organism until Albert Neisser identified the organism to be Neisseria 
gonorrhoeae in 1879. 
 
AETIOLOGY: 
Neisseria gonorrhoeae - gram-negative, non-motile, non-spore forming 
diplococci. The organism is present intracellularly in the polymorphonuclear 
leucocytes.  
 Pathogenic : N. gonorrhoeue and N. meningitidis  
 Non-pathogenic : N. cartarrhalis, N. pharyngis sicca, N. lactamica and N. 
subflava. 
 
MOLECULAR BIOLOGY80: 
 The outer membrane is gram negative and consists of proteins, 
phospholipid and lipo oligosaccharides. Outer membrane proteins are, 
 
Type 1 proteins (Por) - PorA & PorB 
Type 2 protein - Opa protein 
 
 Peptidoglycan: Gonococcal petidoglycan is similar to that of other gram-
negative bacteria, which contain muramic acid and N-acetyl glucosamine 
producing tissue toxin.  
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 Cytoplasmic membrane contains penicillin-binding proteins.  
 
 Pili: Pili are filaments, composed of protein pilin. Long pili are pathogenic 
whereas short pili are non-pathogenic.  
 
 There are 70 different strains of N.gonorrhoeae and can be differentiated 
by auxotyping, serotyping anal genotyping. Auxotype AHU (arginine, 
hypoxanthine, uracil) strains have resistance to killing by normal human serum, 
propensity for asymptomatic male urethral infection an increased likelihood for 
causing bacteremia. 
 
PATHOGENESIS: 
 Primary infection commonly occurs in the columnar epithelium of the 
urethra, para-urethral ducts and glands, cervix, conjunctiva, Bartholin's ducts, and 
rectum. Primary infection may also occur in the stratified squamous epithelium of 
the vagina in prepubertal girls (gonococcal vulvovaginatis). The female urethra 
often escapes infection, owing to its lining with stratified squamous epithelium. 
Total process of tissue infection occurs in the stages: 
 
1. Adherence: Gonococci are able to invade and persist in the blood stream 
by evading host defense. Pili E and Opa are adherence ligands.  
2. Invasion: Endocytosis and pseudopod formation can occur after invasion 
and then transported to the base of the cell called exocytosis followed by 
multiplication intracellularly.  
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3. Tissue damage: Occurs due to lipo oliosaccharide and peptidoglycan 
which stimulates the production of tissue necrosis factor. 
 
ACUTE UROGENITAL GONORRHEA IN WOMEN  
 Uncomplicated gonorrhoea is asymptomatic in more than 50% of the 
cases81. Incubation period is 1 to 14 days. The primary site of infection in females 
is the endocervical canal. 
 
 Endocervicitis - purulent vaginal discharge, dysuria, post-coital bleeding.  
 Speculum examination - copious pus emanating from the external cervical 
os can be visualized.  
 Severe erythema and edema of the cervix 
 Acute skenitis - tenderness in the terminal part of urethra and a bead of pus 
can be expressed at the ductal orifice.  
 Acute bartholinitis - pain, difficulty on walking and heaviness  
 Bartholin abscess  
 Acute Gonococcal vaginitis  
 Gonococcal cystitis and trigonitis - extremely rare.  
 
COMPLICATED UROGENITAL GONORRHEA IN WOMEN  
 Pelvic inflammatory  
 Acute salpingitis   
 Pyosalpinx  
 Tubo-ovarian abscess  
50 
 
 
 Pelvic peritonitis  
 Tubal infertility 
 Ectopic pregnancy  
 Frozen pelvis 
 
GONORRHEA IN PREGNANCY  
 Gonococcal infection has a devastating impact on both the pregnant 
woman and the outcome of pregnancy.  
 Salpingitis and PID 
 Gonococcal chorioamnionitis  
 Septic abortion 
 Premature rupture of membranes 
 Preterm births 
 Prematurity 
 Perinatal mortality 
 Low birth weight 
 Postpartum endometritis 
 Puerperal sepsis 
 Disseminated Gonococcal infection 
 
LAB DIAGNOSIS82: 
Microscopy: 
Specimen is collected with help of sterile cotton wool swabs. In female 
specimen is collected from the endocervix, urethra, rectum or oropharynx. The 
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gonococci are seen as gram-negative diploccoci within Poly Morpho Nuclear 
Leucocytes. The specificity of gram stain is 95-97% from the culture of positive 
male urethral discharge, 40-6-% from endocervical secretion and in asymptomatic 
patients, the smear is mostly negative. 
 
Culture: 
 The culture is the most specific investigation and the commonly used 
selective media for N.gonorrheae,  
 Modified Thayer Martin  
 Chacko Nayar Medium (Trypsin digested beef extract) 
 Martin Lewis media 
 New York City medium.  
 
 The direct plating of organism has better success in growing organism. 
Small pinpoint colonies of 0.5 to 1mm diameter of N.gonorrhoeae can be seen.  
 
 Gonococci are fastidious organisms, requiring an enriched culture media 
for their growth, which also selectively supresses the normal flora. Vancomycin, 
colistin, trimethoprim and nystatin are added to inhibit the growth of bacterial and 
fungal organisms. 
 
OXIDASE REACTION 
A drop of tetra methyl-p-phenylene diamine hydrochloride is poured over 
suspected gonococcal colonies, which quickly turn pink and then dark blue. 
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SUGAR FERMENTATION REACTION  
This is done to differentiate gonorrhea from the other group of Neisseria 
organisms. Gonococcus produces acid only with glucose while meningococcus 
with both glucose and maltose. 
 
OTHERS 
 Rapid carbohydrate utilization test 
 Acidometric test 
 Iodometric test 
 Chromogenic cephalosporin test 
 
TREATMENT 
Uncomplicated Gonococcal infections: 
- Cefixime 400mg orally in a single dose (or) 
- Ceftriaxone 125mg IM in a single dose (or) 
- Ciprofloxacin 500mg orally in a single dose (or) 
- Ofloxacin 400mg orally in a single dose (or) 
- Levofloxacin 250mg orally in a single dose 
 
 All sex partners of patients who have gonococcal infection should be 
evaluated and treated for both gonococcal and chlamydial infection. 
 
CHLAMYDIAL INFECTIONS 
 Chlamydia (from the Greek word meaning "cloak') is caused by the 
bacterium, Chlamydia trachomatis. They are small gram-negative obligate intra-
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cellular microorganisms that preferentially infect squamo-columnar epithelial 
cells. In the genus Chlamydia, C.trachomatis can be differentiated into 18 
serovars: 
 
 Serovars A, B. Ba, and C are associated with trachoma  
 Serovars D-K are associated with genital tract infections 
 L1-L3 are associated with lymphogranuloma venereum.  
` 
CHLAMYDIA LIFECYCLE 
Chlamydia are obligate intracellular bacterial pathogens.  
 The elementary body is infectious, but metabolically inert. Once it attaches 
to a susceptible host cell, it mediates its own Internalization that allows for 
the recruitment of actin with subsequent engulfment of the bacterium.  
 The internalized elementary body within a membrane-bound compartment, 
immediately begins differentiation into the reticulate body. These are 
metabolically active but non-infectious.  
 
PERSISTENCE: 
Chlamydia have the ability to establish long-term associations with host 
cells. When an infected host cell is starved for various nutrients such as amino 
acids, iron, or vitamins, this has negative consequence for Chlamydia since the 
organism is dependent on the host call for these nutrients. The starved chlamydiae 
enter a persistent growth state wherein they stop cell division and become 
morphologically aberrant by Increasing in size83. Persistent organisms remain 
viable as they are capable of returning to a normal growth state once conditions in 
the host cell improve.  
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CLINICAL FEATURES: 
The clinical findings on examination suggestive of chlamydial infection include 
 Endocervical bleeding  
 Mucopurulent endocervical discharge84 
 
Clinical syndromes include, 
 Urethritis 
 Cervicitis 
 Salphingitis  
 Ectopic pregnancy 
 Endometritis 
 Bartholinitis 
 Perihepatitis 
 Arthritis 
 Dermatitis 
 
 Gram stain of appropriately collected mucopurulent endocervical discharge 
from patients having chlamydial endocervicitis usually shows more than 30 
Polymorphonuclear leukocytes per 1000 field, absence of gonococci and 
occasional other bacteria.   
 
LAB STUDIES: 
• Cytological diagnosis 
• Isolation in cell culture 
• Antigen detection 
• Nucleic acid hybridization 
• Detection of chlamydial genes by DNA amplification tests 
• Serology 
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TREATMENT 
 Azithromycin 1gm orally in a single dose 
 All sex partners within preceeding 60 days should be evaluated and treated. 
 
NON-INFECTIVE CONDITIONS: 
CHEMICAL IRRITANTS: 
Using of antiseptics, bath additives, deodorants, detergent spermicides, 
douches and perfumed soaps can cause chemical induced vulvovaginitis. Allergic 
reactions rarely cause the discharge, but often present local reaction. The patient 
should be advised to avoid the use of such substances. Saline bath may help to 
reduce vulvar irritation in the acute phase. Long-term use of tampons has to be 
avoided, preventing vaginal ulceration. Multiple douches may increase the 
amount of discharge, due to drying effect. Douching with commercial preparation 
leads to cause abnormal shifts in vaginal flora85.  
 
FOREIGN BODIES: 
 Foreign body in the vagina is relatively an uncommon cause of increased 
vaginal discharge. Cotton wool from tampons often becomes entwined with the 
thread of Intra uterine copper device and then acts as a focus for secondary 
bacterial infection. Similarly, retained tampons and broken sheath may result in 
persistent bacterial infection, producing a copious, foul smelling discharge.  
 
Most infectious causes may be included or excluded by standard basic 
investigation. Non-infective leukorrhea (NIL) should be considered as the 
diagnosis in women with abnormal vaginal discharge when following criteria are 
fulfilled86. 
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ENDOCERVICAL SECRETIONS: 
• Absence of visible mucopus 
• Absence of microscopic mucopus 
 
VAGINAL SECRETIONS: 
• Absence of trichomonad motility 
• Absence of filamentous elements 
• Clue cells less than 20% of total vaginal epithelial cells 
• Numerous lactobacilli 
• PMN leukocytes:epithelial cell ratio is 1:1 or less 
 
 If all 7 criteria are fulfilled, vaginal and cervical infections can be safely 
excluded. In NIL, the striking microscopic findings in vaginal secretion are of an 
abundance of large rods and normal vaginal epithelial cells. 
 
  
Aims & Objectives 
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AIMS AND OBJECTIVES 
 
1. To determine the Prevalence of vaginal discharge in HIV infected and 
noninfected women 
2. To find out socio-demographic variables associated with vaginal discharge in 
HIV positive women 
3. To compare the infectivity pattern between HIV infected and noninfected 
women.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
Prospective study  
 
SAMPLE 
The study population comprised of 200 women with complaints of vaginal 
discharge attending the Institute of Venereology Government General Hospital, 
Chennai from June 2017 to May 2018. 
 
METHODS 
The study patients were interviewed regarding their age, educational status, 
marital status, presenting complaints, sexual history, past history of venereal 
diseases and their condom use. 
 
All the patients were counseled on STD/ HIV, genital hygiene, sexual 
practices, regular treatment and follow up. They were given pre and post test 
counselling. 
 
All the patients underwent a complete physical examination and genital 
examination. Except antenatal women and women during menstruation, other 
patients were examined with Cuscos bivalved self retaining vaginal  speculum. 
All these patients were clinically analyzed for the genital manifestations and 
supported by laboratory diagnosis. 
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Sera from all the participants were VCTC for screening HIV after informed 
consent and providing pre and post test counselling. In patients who were found to 
be HIV positive, blood was collected for CD4 count analysis. 
 
Serological tests for syphilis including blood VDRL and TPHA were 
performed. Blood was also collected for HBsAg and Anti HCV antibodies.  
 
From vaginal smear, the following tests were done 
 pH of the discharge 
 Whiff test by adding few drops of 10% KOH (Potassium hydroxide) 
to the genital discharge. 
 Wet film with one drop of normal saline for Trichomonas vaginalis 
and clue cells. 
 10% KOH wet mount preparation for Candida albicans and culture 
with SDA (Saborauds Dextrose Agar) for suspective cases. 
 Grams stain to identify Neisseria gonorrhea from endocervix, 
Lactobacillus, clue cells and Candida hyphae from vaginal 
discharge. 
 
In addition to the routine examination of urine, culture of Neisseria 
gonorrhoea from urine specimen and endo cervix was done. 
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Routine baseline laboratory analysis including complete blood count, urine 
for albumin, sugar deposits, ultra sound abdomen were done for all patients. Liver 
function test, Renal function test, Random blood sugar, chest x-ray, ECG, sputum 
smear for AFB, Mantoux test, blood and urine culture sensitivity  were also done 
for the needed patients. 
 
In needed symptomatic patients’ opinion from concerned specialists such 
as Dermatology, Obstetrics & Gynecology, Dental, Ophthalmology, Chest clinic, 
Cardiology, Neurology, Nephrology, Urology and Gastroenterology were 
obtained. Patients were offered standard treatment according to clinical condition 
and prophylaxis for opportunistic infections. 
 
  
Observations & Results 
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OBSERVATIONS AND RESULTS 
 
 A total of 200 women who fit the eligibility criteria were enrolled into the 
study between April 2017 and March 2018. All cases were evaluated clinically 
and essential investigations necessary for diagnosis were carried out.  
HIV No of patients  n=200 (%) 
Positive 17 (8.5%) 
Negative 183 (91.5%) 
 
 
 
 Among 200 women studied, 17 (8.5%) were confirmed to be HIV positive 
and 183 (91.5%) were HIV negative.  
 
 Comparison of variables between HIV positive and HIV negative women 
having vaginal discharge were listed below. 
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COMPARISON OF AGE GROUP WITH HIV STATUS 
 
Variable 
Age group (years) 
<=20 21 - 30 31- 40 >41 
HIV 
+ve 1 (5.9%) 3 (17.6%) 11 (64.7%) 2 (11.8%) 
-ve 8 (4.4%) 79 (43.2%) 58 (31.7%) 38 (20.8%) 
Chi- square value (Fischer Exact) – 8.094 
p value 0.04 (statistically significant) 
 
 
 
 
 On comparing HIV negative and HIV positive participants having vaginal 
discharge with age group, maximum number of HIV positive and negative women 
were in the age group of 31-40 years (64.7%) and 21-30 years (43.2%) 
respectively. This is found to be statistically significant (p=0.04). 
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COMPARISON OF EDUCATION WITH HIV STATUS 
 
Variable 
Education 
Illiterate Primary school Middle school 
High 
school Degree 
HIV 
+ve 11 (64.7%) 3 (17.6%) 2 (11.8%) 1 (5.9%) 0 (0%) 
-ve 102 (55.7%) 42 (23%) 16 (8.7%) 11 (6%) 
12 
(6.6%) 
Chi- square value (Fischer Exact) – 1.689 
p value 0.887 (Not statistically significant) 
 
 
 
 
It was found from the above data that, majority of women with vaginal discharge 
were illiterate, with 64.5% in HIV positive and 55.7% in HIV negative group. 
None of the HIV positive women have completed degree, whereas 6.6% were 
well educated in HIV negative group. 
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COMPARISON OF OCCUPATION WITH HIV STATUS 
 
Variable 
Occupation 
Housewife Working Student 
Commercial 
Sex Worker 
(CSW) 
HIV 
Positive 8 (47.1%) 6 (35.3%) 0 (0%) 3 (17.6%) 
Negative 113 (61.7%) 48 (26.2%) 19 (10.4%) 3 (1.6%) 
Chi- square value (Fischer Exact) – 16.080 
p value 0.009 (statistically significant) 
 
 
 
 
 
Of the 17 HIV positive women, 8(47.1%) were housewives and 3(17.6%) were 
commercial sex workers (CSW). Whereas, only 1.6% were CSWs in HIV 
negative women 
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COMPARISON OF MARITAL STATUS WITH HIV STATUS 
 
 
 
 
 
On analysing the marital status of the study population, most of them were found 
to be housewives irrespective of the HIV status. 41.2% of HIV positive women 
were divorced/separated from the husband which is statistically significant with 
5.5% in HIV negative participants. 
Variable 
Marital status 
Married Unmarried Divorced/separated 
HIV 
Positive 8 (47.1%) 2 (11.8%) 7 (41.2%) 
Negative 156 (85.2%) 17 (9.3%) 10 (5.5%) 
Chi- square value (Fischer Exact) – 26.205 
p value 0.001 (statistically significant) 
66 
 
 
 
 
COMPARISON OF NUMBER OF SEX PARTNERS WITH HIV STATUS 
 
Variable 
Number of sex partner 
Single Multiple 
HIV 
Positive 10 (58.8%) 7 (41.2%) 
Negative 151 (82.5%) 32 (17.5%) 
Chi- square value (Fischer Exact) – 5.561 
p value 0.027 (statistically significant) 
 
 
 
 
Nearly half (41.2%) of the HIV positive women had multiple sex partners, while 
there were only 17.5% in HIV negative women. 
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COMPARISON OF EMC/PMC WITH HIV STATUS 
 
Variable 
Sexual exposure 
Extra Marital 
Contact (EMC) 
Pre-Marital 
Contact (PMC) 
HIV 
Positive 4 (57.1%) 3 (42.9%) 
Negative 17 (53.1%) 15 (46.9%) 
Chi- square value (Fischer Exact) – 0.037 
p value 1.00 (not statistically significant) 
 
 
 
 
 
 
 
 Among the women having multiple sex partners, extra marital contact was 
found to be almost equal in HIV negative (53.1%) and HIV positive (57.1%) 
women. 
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COMPARISON OF LAST SEXUAL CONTACT WITH HIV STATUS 
 
Variable 
Last sexual contact 
< 1 week 1 week – 1 month 
1 month – 
6 months > 6 months 
HIV 
Positive 10 (58.8%) 3 (17.6%) 2 (11.8%) 2 (11.8%) 
Negative 51 (27.9%) 88 (48.1%) 21 (11.5%) 23 (12.6%) 
Chi- square value (Fischer Exact) – 8.064 
p value 0.033 (statistically significant) 
 
 
 
 
 In this study, majority of HIV positive women (58.8%) had their last sexual 
contact in less than one week. Only 2(11.8%) had last sexual contact 6 months 
back. 
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COMPARISON OF MODE OF SEX WITH HIV STATUS 
 
Mode of sex 
HIV status 
Positive Negative 
Penovaginal alone 14 (82.3%) 174 (95%) 
Penovaginal and 
Peno oral 2 (11.7%) 7 (3.9%) 
Penovaginal and 
Peno anal 1 (5.88%) 2 (1.1%) 
Chi square (Fischer exact) 4.82 
p value 0.08 (not statistically significant) 
 
 
 
 
 
 In this study all the women had peno vaginal route as the primary mode of 
sex, but 2 (11.7%) patients in HIV positive group and 7 (3.9%) patients in 
negative group practised peno-oral route along with penovaginal route. Peno-anal 
route was practised by 1 (5.88%) HIV positive and 2 (1.1%) HIV negative 
women. More than half of the women with vaginal discharge used condom 
consistently and few of them used irregularly. 
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COMPARISON OF PAST HISTORY OF SEXUALLY TRANSMITTED 
DISEASES (STD) WITH HIV STATUS 
 
Variable 
Past history of STD 
Present Absent 
HIV 
Positive 11 (64.7%) 6 (35.3%) 
Negative 65 (35.5%) 118 (64.5%) 
Chi- square value (Fischer Exact) – 5.624 
p value 0.019 (statistically significant) 
 
 
 
 
 In this study, 11 (64.7%) and 65 women (35.5%) had past history of 
sexually transmitted infections in HIV positive and HIV negative category 
respectively. 
 
  
71 
 
 
 
COMPARISON OF DISTRIBUTION OF PAST STDs WITH HIV STATUS 
 
Variable 
Distribution of past STD 
Genital Ulcer 
Disease 
(GUD) 
Vaginal 
Discharge 
Syndrome (VDS) 
Others  
HIV 
Positive 5 (45.5%) 5 (45.5%) 1 (9.1%) 
Negative 8 (12.3%) 54 (83.1%) 3 (4.6%) 
Chi- square value (Fischer Exact) – 8.116 
p value 0.020 (statistically significant) 
 
  
 
 
 
 The above data shows that, vaginal discharge and genital ulcer disease 
were equally present (45.5%) among HIV positive women, and 83.3% had vaginal 
discharge, 12.3% had genital ulcer disease and 4.6% had other STIs in HIV non 
infected category. 
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COMPARISON OF NATURE OF VAGINAL DISCHARGE WITH HIV 
STATUS 
Variable 
Nature of Discharge 
Curdy white Mucoid Mucopurulent 
HIV 
+ve 5 (29.4%) 6 (35.29%) 6 (35.29%) 
-ve 27 (14.7%) 136 (74.3%) 20 (30.10%) 
Chi- square value (Fischer Exact) –1.874 
p value 0.440 (not statistically significant) 
 
 
 
 On analysing the type of abnormal vaginal discharge, 5 (29.4%) of them 
had curdy white discharge. Mucoid and mucopurulent discharge were seen in 6 
(35.29%) patients each in HIV positive group. In that, 1 patient had frothy vaginal 
discharge. 
 
 In HIV negative category, more than of the patients (74.3%) had mucoid 
discharge, 20 (30.1%) were with mucopurulent discharge and 14.7% with curdy 
white discharge. Among these, frothy discharge was seen in 4 patients. 
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COMPARISON OF AMOUNT OF VAGINAL DISCHARGE WITH HIV 
STATUS 
Amount of 
discharge 
HIV status 
Positive  Negative  
Scanty 5 (29.4%) 27 (14.7%) 
Moderate 6 (35.2%) 136 (74.3%) 
Profuse 6 (35.2%) 20 (10.9%) 
Chi square (Fischer exact) 12.52 
p value 0.001 (statistically significant) 
 
 
 
 
 Among 17 HIV positive women, 5 (29.4%) had scanty vaginal discharge, 6 
(35.2%) had moderate and profuse vaginal discharge each. In HIV negative group, 
27 (14.7%) had scanty discharge, 136 (74.3%) had moderate and 20 (10.9%) had 
profuse discharge. 
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COMPARISON OF SYMPTOMS WITH HIV STATUS 
 
Symptoms 
HIV status Chi square  
(Fischer exact) 
p value Positive Negative 
Vulval itching 
Present 9 (52.9%) 109 (59.5%) 0.28 
0.595 (not significant) Absent 8 (47.1%) 74 (40.4%) 
Dysuria 
Present 8 (47.1%) 56 (30.6%) 1.936 
0.164 (not significant) Absent 9 (52.9%) 127 (69.3%) 
Dyspareunia 
Present 3 (17.6%) 32 (17.4%) 0.0003 
0.986 (not significant) Absent 14 (82.3%) 151 (82.5%) 
Lower 
abdominal pain 
Present 2 (11.8%) 21 (11.4%) 0.0013 
0.971 (not significant) Absent 15 (88.2%) 162 (88.6%) 
 
 
 Vaginal itching was found to be the most common symptom in addition to 
vaginal discharge irrespective of the HIV status (52.9% in HIV positive versus 
59.5% in HIV negative). Dysuria was present more commonly in HIV positive 
women (47.1%) compared to negative women (30.6%). Dyspareunia and lower 
abdominal pain was present in same number of women in relation to their HIV 
status. 
75 
 
 
 
COMPARISON OF VULVAL EXAMINATION WITH HIV STATUS 
 
 
 
 41.1% and 18% were found to have erythema on examination of genitalia 
in HIV positive and negative women respectively. This was found to be 
statistically significant. Soddening was present in 35.3% of HIV infected and 
22.9% of uninfected women. 23.5% HIV positive and 8.7% HIV negative women 
had excoriation on local examination. 
 
Vulval Examination 
HIV status Chi square 
(Fischer exact) 
p value Positive Negative 
Erythema 
Present 7 (41.1%) 33 (18%) 5.20 
0.022 (significant) Absent 10 (58.8%) 150 (82%) 
Soddening 
Present 6 (35.3%) 42 (22.9%) 1.299 
0.254 (not significant) Absent 11 (64.7%) 141 (77.1%) 
Excoriation 
Present 4 (23.5%) 16 (8.7%) 3.77 
0.052 (not significant) Absent 13 (76.5%) 167 (91.3%) 
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COMPARISON OF CERVIX FINDINGS WITH HIV STATUS 
Variable 
Cervix 
Healthy Erosion Ectopy Hypertrophic cervix 
Strawberry 
cervix 
HIV 
+ve 7 (41.2%) 6 (35.3%) 3 (17.6%) 1 (11.1%) 0 (0%) 
-ve 141 (77%) 25 (13.7%) 8 (4.4%) 8 (4.4%) 1 (0.5%) 
Chi- square value (Fischer Exact) –12.55 
p value 0.008 (statistically significant) 
 
 
 
 The above analysis shows the appearance of cervix on speculum 
examination in the study group. Both categories showed healthy cervix as the 
most common presentation (41.2% in HIV infected versus 77% in non-infected). 
Whereas, cervical erosion was more in case of HIV infected (35.3%) than in non-
infected (13.7%). Only 1 (0.5%) of the participant was found to have strawberry 
cervix in HIV negative group and none of the HIV positive women showed 
strawberry cervix. 
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COMPARISON OF WHIFF TEST WITH HIV STATUS 
 
Variable 
Whiff test 
Positive Negative 
HIV 
+ve 4 (23.5%) 13 (76.5%) 
-ve 65 (35.5%) 118 (64.5%) 
Chi- square value (Fischer Exact) –0.990 
p value 0.428 (not statistically significant) 
 
 
 
 
 About 23.5% were positive for whiff test (on adding 10% potassium 
hydroxide to the vaginal discharge) in HIV infected cases and 35.5% were 
positive in HIV uninfected patients. 
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COMPARISON OF pH STUDY WITH HIV STATUS 
 
Variable 
pH 
< 5 >=5 
HIV 
+ve 9 (52.9%) 8 (47.1%) 
-ve 79 (43.2%) 104 (56.8%) 
Chi- square value (Fischer Exact) –0.603 
p value 0.456 (not statistically significant) 
 
 
 
 
 pH of less than 5 was seen in 9 (52.9%) patients out of 17 HIV infected 
women and 79 (43.2%) patients in HIV uninfected cases. 
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COMPARISON OF MICROSCOPIC EXAMINATION OF VAGINAL 
SMEAR WITH HIV STATUS 
 
Variable 
Microscopy 
Pus 
cells 
Clue 
cells 
Clue 
cells + 
PSH 
Pseudohyphae TV TV + PSH 
Secondary 
organisms Negative 
HIV 
+ve 2 (11.8%) 
4 
(23.5%) 
1 
(5.9%) 
7 
(41.2%) 
2 
(11.8%) 
0  
(0%) 
1 
(5.9%) 0 (0%) 
-ve 4 (2.2%) 
73 
(39.9%) 
1 
(0.5%) 
51 
(27.9%) 
27 
(14.8%) 
1 
(0.5%) 
3 
(1.6%) 
23 
(12.6%) 
Chi- square value (Fischer Exact) – 21.372 
p value 0.021 (statistically significant) 
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 Out of 17 HIV positive women, the vaginal smear study revealed, clue 
cells in 4 (23.5%) patients, pseudohyphae in 7 (41.2%), trichomonas in 2 (11.8%), 
pus cells in 2 (11.8%) and secondary organisms in 1 (5.9%) patient. 1 (5.9%) 
patient showed both clue cells and pseudohyphae in gram stain.  
 
 Among 183 HIV negative women, gram stain showed clue cells in 73 
(39.9%) patients, 10% KOH showed pseudohyphae in 51(27.9%), wet mount 
showed trichomonas in 27 (14.8%) patients. Co-infection like trichomonas and 
pseudohyphae, pseudohyphae and clue cells were seen in 1 (0.5%) case each. No 
organisms were found in 23 (12.6%) women. 
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COMPARISON OF MICROSCOPIC EXAMINATION OF CERVICAL 
SMEAR WITH HIV STATUS 
 
Variable 
Microscopy 
> 30 Pus cells Negative 
HIV 
+ve 3 (17.6%) 14 (82.4%) 
-ve 7 (3.8%) 176 (96.2%) 
Chi- square value (Fischer Exact) – 6.256 
p value 0.042 (statistically significant) 
 
 
 
 
 
 Cervical smear study had revealed, more than 30 pus cells in 3 (17.6%) 
cases of HIV infected women and 7 (3.8%) cases of HIV uninfected women. 
None of them showed intracellular organisms in microscopic examination of 
cervical smear. 
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COMPARISON OF CULTURE OF VAGINAL DISCHARGE WITH HIV 
STATUS 
 
Variable 
Culture 
Candida 
albicans 
Candida 
nonalbicans 
Trichomonas 
(TV) 
Trichomonas 
(TV) + 
Candida 
nonalbicans 
Negative 
HIV 
+ve 2 (11.8%) 6 (35.3%) 2 (11.8%) 0 (0%) 7 (41.2%) 
-ve 10 (5.5%) 42 (23%) 29 (15.8%) 1 (0.5%) 101 (55.2%) 
Chi- square value (Fischer Exact) –2.842 
p value 0.376 (not statistically significant) 
 
 
 
 
 
 Candida non albicans was the most common organism isolated in culture 
of vaginal discharge in both HIV positive (35.3%) and negative women (23%). 
Only 5.5% of Candida albicans was present in culture of vaginal discharge of HIV 
negative women. 
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COMPARISON OF ETIOLOGICAL DIAGNOSIS WITH HIV STATUS 
 
Variable 
Diagnosis 
Bacterial 
Vaginosis 
(BV) 
BV+VVC Trichomoniasis (TV) 
Vulvo      
vaginal 
candidiasis 
(VVC) 
TV 
+VVC Cervicitis Others 
HIV 
+ve 4 (23.5%) 1 (5.9%) 2 (11.8%) 7 (41.2%) 0 (0%) 3 (17.6%) 0 (0%) 
-ve 73 (39.9%) 1 (0.5%) 29 (15.8%) 51 (27.9%) 
1 
(0.5%) 7 (3.8%) 
21 
(11.5%) 
Chi- square value (Fischer Exact) –14.615 
p value 0.031 (statistically significant) 
 
 
 
 
 Vulvovaginal candidiasis (41.2%) was the most common cause of 
abnormal vaginal discharge in HIV infected women followed by bacterial 
vaginosis and trichomoniasis compared to HIV uninfected women, where 
bacterial vaginosis (39.9%) was the common cause. Cervicitis was seen in 17.6% 
of HIV positive and 3.8% of HIV negative women. Out of 183 HIV negative 
patients, 21 (11.5%) were found to have no organisms and diagnosed as normal 
vaginal discharge. Whereas, all the HIV infected patients with vaginal discharge 
were found to have infective etiology. 
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COMPARISON OF VDRL RESULTS WITH HIV STATUS 
 
Variable 
VDRL 
Reactive Non-reactive 
HIV 
Positive 1 (5.9%) 16 (94.1%) 
Negative 4 (2.2%) 179 (97.8%) 
Chi- square value (Fischer Exact) – 0.872 
p value 0.362 (not statistically significant) 
 
 
 
 
 Out of 17, 1 (5.9%) was found to be reactive for VDRL in HIV positive 
category. And 4 (2.2%) patients were reactive in HIV negative category. 
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COMPARISON OF TPHA RESULTS WITH HIV STATUS 
 
Variable 
TPHA 
Positive Negative 
HIV 
Positive 1 (5.9%) 16 (94.1%) 
Negative 6 (3.3%) 177 (96.7%) 
Chi- square value (Fischer Exact) – 0.312 
p value 0.468 (not statistically significant) 
 
 
 
 
 TPHA was found positive in 1 patient who was also reactive for VDRL 
in HIV sero-positive category and 6 patients showed positive TPHA in HIV sero-
negative category. 
 
 From VDRL and TPHA results, it is concluded that, 1 HIV positive 
women had secondary syphilis. In HIV uninfected women with vaginal discharge, 
2 patients were found to have late latent syphilis and 4 patients had early latent 
syphilis.  
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CD4 COUNT IN HIV POSITIVE PATIENTS 
 
Variable No of HIV positive 
CD4 count  
(N = 17) 
< 200 2 (11.7%) 
201-500 5 (29.4%) 
> 500 10 (58.8%) 
 
 
 
 
 
 Among 17 HIV positive cases with vaginal discharge, 2 (11.7%) had CD4 
counts of less than 200, 5 (29.4%) women had CD4 count between 200-500 and 
10 (58.8%) had more than 500 counts. 
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COMPARISON OF CD4 COUNT WITH ETIOLOGICAL DIAGNOSIS 
 
Variable 
Diagnosis 
BV BV+VVC TV VVC Cervicitis 
CD4 
<200 0 (0%) (0%) 2 (100%) 0 (0%) 0 (0%) 
201-
500 2 (40%) 1 (20%) 0 (0%) 1 (20%) 1 (20%) 
>500 2 (20%) 0 (0%) 0 (0%) 6 (60%)  2 (20%) 
Chi- square value (Fischer Exact) – 21.12 
p value 0.033 (statistically significant) 
  
 
 
 
 This table shows that, all the patients with trichomoniasis were having CD4 
count of less than 200. Half of the patients with bacterial vaginosis had CD4 count 
between 200-500 and remaining half of them had less than 500 counts. 
Vulvovaginal candidiasis was found in 6 patients with CD4 count >500 compared 
to 1 patient with CD4 count between 200-500. 
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COMPARISON OF PARTNER’S HIV STATUS WITH STUDY 
PARTICIPANTS 
 
Variables 
Partner’s HIV status 
Positive Negative Unknown 
HIV status in study 
participants 
Positive 6 (35.3%) 7 (41.2%) 4 (23.5%) 
Negative 11 (6%) 116 (63.4%) 56 (30.6%) 
Chi- square value (Fischer Exact) – 17.19 
p value 0.002 (statistically significant) 
 
 
 
 
 
 Majority of the partners screened for HIV were found to be positive in HIV 
infected group (35.5%) compared to 6% in uninfected group.  
 
 
 
 
 
Clinical Images 
  
CLINICAL IMAGES 
 
Image 1: Speculum examination showing mucopurulent vaginal discharge 
 
 
Image 2: Speculum examination showing frothy vaginal discharge 
 Image 3: Speculum examination showing adherent curdy white vaginal discharge 
 
 
Image 4: Erythema, Soddening and erosions in vulva 
 Image 5: Speculum examination showing cervical erosion 
 
 
Image 6: Gram stain of vaginal smear showing clue cells 
 
 Image 7: 10% Potassium hydroxide mount showing pseudohyphae and spores 
 
 
Image 8: Wet mount with normal saline showing Trichomonas vaginalis 
 
 Image 9: Sabouraud’s dextrose agar showing white to cream coloured smooth 
colonies 
 
 
Image 10: CHROMagar showing different species of candida 
Discussion 
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DISCUSSION 
 
During the study period, 200 women with complaints of vaginal discharge 
were studied in detail. By clinical and laboratory investigations, 17 (8.5%) of 
them were found to be HIV positive and remaining 183 (91.5%) were HIV 
negative.  
 
The analysis of age in women with vaginal discharge shows that mean age 
for HIV positive women was 33 years, with majority of women in the age group 
of 31-40 years. These observations were similar to Oyewole87 et al study who 
showed that the group of women that were heavily infected are those that are 
found between the age group of 21-30 and 31-40 years. This shows that vaginal 
discharge was more common among sexually active and childbearing age group. 
The analysis also reveals that 9 (4.5%) patients belong to 18-20 years of age. 
These are the patients who should be the target group for prevention. 
 
More than half of the women (64.7%) were illiterate in HIV positive 
category, which explains the lack of awareness about safe sexual practices. The 
prevalence of vaginal discharge was low in women who had higher education, 
irrespective of their HIV status. 
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Majority of women were housewives, irrespective of their HIV status. 
About 17.6% of HIV positive women were commercial sex workers. More 
intensive dissemination of the knowledge should be directed to the commercial 
sex workers regarding the need for safer sex practices. 
 
Majority of the women in this study were married (HIV positive - 47.1% 
versus HIV negative - 85.2%), which leads to increase in spread of infections in 
their partners. HIV positive women were more likely to be divorced or separated 
(41.2%) than the HIV negative women (5.5%). This shows that they would have 
contracted infections from extra-marital contacts. This is in congruence with 
Isaika-Lawal SA88 et al study.  
 
In this study, 41.3% of HIV positive women were having multiple partners 
compared to 17.5% in HIV negative women. There was statistically significant 
difference between the two groups of women with regards to marital status (P = 
0.027).  This shows that increased number of partners increases the chance of 
getting vaginal infections.  
 
Among 7 HIV positive women having multiple partners, 4 of them were 
having extra marital contact and 3 of them had pre-marital contact. 
 
On comparing the last sexual contact between HIV positive and negative 
women, 58.8% of HIV positive women had their last sexual contact in less than a 
week ago, while majority of HIV negative women had contact between 1week –
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1month (48.1%). This implies that most of the HIV positive women were sexually 
active recently, which can lead to high rates of transmission of infections. 
 
The commonest mode of sex was normal peno vaginal route (100%) in 
both HIV positive and negative women having vaginal discharge. Unnatural mode 
of sex like peno-oral and peno-anal route were practised more commonly by HIV 
positive women (11.7% and 5.8%). Anal sex is the riskiest sexual behaviour for 
transmitting and acquiring HIV. Safer sex practices should be advised in these 
patients to avoid other sexually transmitted infections. 
 
In our study, 64.7% were reported to have past history of STI in HIV 
positive group and 35.5% in HIV negative group. On evaluation of the data, 
genital ulcer disease was much more common among women infected with HIV 
than women not infected with HIV (45.5% versus 12.3%). Therefore, it is 
imperative to treat genital ulcers, as it increases the transmission of HIV and other 
sexually transmitted infections. Pinto VM89 et al study showed highest proportion 
of women with Human Papilloma Virus infection (44%) followed by genital ulcer 
(17.9%) in HIV infected women.  
 
Mucoid discharge was found to be the most common nature of vaginal 
discharge seen in both HIV infected (58.8%) and non-infected women (50.8%). 
This emphasis the need for more intensive dissemination of knowledge in 
differentiating normal from abnormal vaginal discharge among women of 
reproductive age group. 
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On analysing the amount of vaginal discharge, moderate and profuse 
discharge were equally seen in HIV positive women (35.2%). Profuse discharge 
was seen only in 10.9% of women without HIV. None of the women had a 
physiological cause for profuse discharge. More emphasis should be laid upon to 
educate these patients, not to delay evaluation, treatment to prevent the morbidity 
of the potentially treatable disease. 
 
The majority of women with vaginal discharge had another coexisting 
complaint. In our study, the most common symptom reported in addition to 
vaginal discharge is vaginal itching followed by dysuria and dyspareunia. 
 
On examination of genitalia, erythema was significantly more common 
among HIV positive women (41.1% versus 18%) and soddening was seen more 
among HIV negative women (35.3% versus 22.9%). 
 
35.3% of HIV positive women with vaginal discharge had cervical 
erosions on speculum examination, while only 13.7% HIV negative women had 
cervical erosions. On further analysis, it was found that strawberry cervix was 
found only in one HIV non infected patient. Patients with cervical erosion were 
sent to gynaecology department for Pap smear study to rule out carcinoma insitu 
and were followed up if necessary. 
 
About 23.5% were positive for whiff test in HIV infected cases and 35.5% 
were positive in HIV uninfected patients. pH of more than 5 was seen in 8 
(47.1%) patients out of 17 HIV infected women and 104 (56.8%) patients in HIV 
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uninfected cases. The pH evaluation of the vaginal discharge gives a clear 
distinction in differentiating between pathogenic and non-pathogenic discharge. 
This is a simple bedside test. It helps the clinician to plan for more specific 
investigations in the management of these patients. 
 
On analysing the microscopic findings of vaginal smear, women infected 
with HIV were more likely to have pseudohyphae (41.2%) than women not 
infected with HIV (27.9%). This is comparable with Sebitloane90 et al study 
(39.2% versus 30%). Whereas in HIV negative women, clue cells (39.9%) were 
found to be the predominant finding.  
 
On comparing microscopic finding of cervical smear with HIV status, HIV 
sero-positive women (17.6%) had significantly more number (>30) of pus cells 
compared to HIV sero-negative women (3.8%). 
 
On analysing the cause of abnormal vaginal discharge, the following were 
observed. In HIV positive women, vulvovaginal candidiasis (41.2%) was 
observed to be the most common cause of abnormal vaginal discharge. This is in 
close agreement with Sharma et al study, where the most common cause was 
candidiasis (34%). Also the results of our study comply with Dimple91 et al study, 
where also the most common cause of vaginal discharge came out to be 
candidiasis. Bacterial vaginosis was seen in 4 (23.5%) patients, trichomoniasis in 
2 (11.8%), cervicitis in 3 (17.6%) patients. Mixed infection (bacterial vaginosis 
and trichomoniasis) were seen in 5.9% of women. This was slightly lower than 
the prevalence obtained by various studies91,92, which was about 8-10%. 
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In our study, in case of HIV negative women, it was seen that the most 
common cause of vaginal discharge was bacterial vaginosis (39.9%). This was 
followed by candidiasis (27.9%), trichomoniasis (15.8%), cervicitis (3.8%) and 
mixed infection (1%). This is comparable with Dimple91 et al study, where the 
most common cause of vaginal discharge in HIV negative women also came out 
to be bacterial vaginosis (29%). In the remaining 11.5% of patients, diagnosis 
could not be made out with the microbiological diagnostic approach. Similarly 
Vijayalakshmi D93 et al study showed that in 19.5% of the patients complaining of 
vaginal discharge, diagnosis could not be reached using any of the diagnostic 
approaches under consideration. This group of patients probably may have normal 
physiological discharge or less frequently viral vaginitis, aerobic vaginitis or vagi-
nal lactobacillosis which are not routinely detected. 
 
Cervicitis was found to be more common in HIV infected women than HIV 
uninfected women (17.6% versus 3.8%).These patients pose a higher risk to their 
sexual partners as they have more mucosal inflammation thus enhancing the 
spread of HIV to their partners. Mixed infection in HIV negative were relatively 
less compared to HIV positive women (1% versus 5.9%).  
 
The study group had 5 patients who were reactive to VDRL test and 7 
patients who were positive for TPHA test. 1 HIV positive patient had secondary 
syphilis. In HIV uninfected women with vaginal discharge, 2 patients were found 
to have late latent syphilis and 4 patients had early latent syphilis.  
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All the women irrespective of their HIV status showed negative results 
with serological tests for Hepatitis B and Hepatitis C. 
 
In our study, only 11.7% of women were associated with CD4 count of less 
than 200, which is less compared to Goel94 et al study where 30% of women had 
CD4 count <200. The remaining 88.3% had counts of more than 200. This was 
found to be statistically significant. This shows that prevalence of HIV sero-
positive women with lower levels of CD4 count are decreasing, because of early 
diagnosis of HIV and appropriate institution of HAART.  
 
On analysing CD4 count with etiological diagnosis, trichomoniasis was 
significantly associated with low levels of CD4 count (<200), showing that low 
levels of CD4 count are associated with significant trichomonas vaginalis 
infection due to epithelial barrier disruption and by changes in innate and adaptive 
immunity in the female genital tract. 
 
Most of the partners screened for HIV were found to be positive in HIV 
infected women category (35.5%) compared to 6% in uninfected group. Among 
140 partners who were screened, 24 Partners were found to have candidal 
balanoposthitis and 2 had trichomoniasis. Thus, partner screening should be 
emphasised as vaginal inflammation due to abnormal vaginal discharge can 
increase the vaginal shedding of HIV, thereby transmitting it to their partners. 
  
Limitations 
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LIMITATIONS 
 
The study is based on a number of two hundred patients. A study of larger 
magnitude may have a better statistical significance. 
 
The study done is based on the outcome of microscopic smear examination 
and laboratory culture for various organisms causing abnormal vaginal discharge. 
This was done over a period of time. Hence it may be varied over a period of time 
thus producing a mild difference in the outcome of the lab reports. 
 
Other causes like Chlamydial infections should be looked in for. The 
present study do not employ laboratory methods for identifying Chlamydia in the 
vaginal discharge. 
 
  
Conclusion 
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CONCLUSION 
 
It is imperative from the study that a significant amount of HIV positive 
patients are suffering from abnormal vaginal discharge. Bacterial vaginosis, 
Trichomoniasis and Vulvovaginal Candidiasis are the principal causes for the 
abnormal vaginal discharge.  
 
More emphasis should be laid upon patients who are HIV sero-positive, 
ensuring a complete cure from these diseases as they already suffer from 
immunocompromised status. These patients need an extended course of treatment 
when compared to HIV seronegative patients and are more prone from recurrent 
infections. Appropriate counseling is manadatory for their sexual partners too. 
 
The detailed evaluation of the obtained data from the clinical and 
laboratory assessment of abnormal vaginal discharge in HIV positive and negative 
patients has given a clear insight of the problem. The outcome will help the health 
policy makers, Venereology Physicians and Venereal Microbiologists to give a 
better outcome in the approach, evaluation, laboratory methods and treatment of 
these diseases. 
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Annexures 
ABBREVIATIONS 
 
AIDS   - Acquired immunodeficiency syndrome 
HIV   - Human Immunodeficiency Virus 
BV   - Bacterial vaginosis 
TV   - Trichomonas vaginalis 
VVC   - Vulvo Vaginal Candidiasis 
SLPI   - Secretory Leukocyte Protease Inhibitor 
DNA   - Deoxyribo Nucleic Acid 
RNA   - Ribo Nucleic Acid 
H2O2   - Hydrogen peroxide 
IL   - Interleukin 
CD   - Cluster Differentiation 
TNF   - Tumour Necrosis Factor 
PID   - Pelvic Inflammatory Disease 
IVF   - In Vitro Fertilization 
CDC   - Centre for Disease Control 
STI   - Sexually Transmitted Infections 
STD   - Sexually Transmitted Diseases 
CO2   - Carbondioxide 
NAAT  - Nucleic Acid Amplification Tests 
ELISA  - Enzyme Linked Immuno Sorbent Assay 
NIL   - Non-infective leucorrhea 
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1 23 PS M W 1w-1m     single - - dy - - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
2 30 ill M HW 1w-1m     multiple EMC VI DP - mucopurulent Profuse H TV neg TV neg >5 trichomoniasis P VDS neg NR neg U PV
3 19 HS UM Stu 1w-6m     single - VI - - - mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
4 22 D UM Stu 1w-6m     single - - - - - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
5 35 ill M HW 1w-1m     single - VI - - - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
6 31 ill M HW <1w      single - VI - - - curdy white Moderate Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
7 41 MS M HW <1w      single - VI - - - mucoid Moderate EX H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
8 48 ill M HW <1w      single - VI dy DP - curdy white Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
9 54 ill M HW >6m  single - VI - - - curdy white Profuse Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
10 39 ill M HW 1w-6m     single - - - - - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
11 37 ill D/S HW >6m  single - - - - - mucoid Scanty Ect SO >30 PC neg neg >5 cervicitis P VDS pos NR neg 843 neg PO
12 27 ill M HW 1w-1m     single - - dy - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
13 24 ill M HW <1w      single - VI - mucoid Profuse H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
14 49 ill D/S HW >6m  multiple PMC - mucoid Profuse H TV neg TV neg >5 trichomoniasis P GUD neg NR neg U PV
15 26 PS M HW <1w      single VI - mucopurulent Moderate E clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
16 31 PS M HW 1w-1m     multiple PMC VI dy - mucoid Moderate Er Sod EX E PSH neg CNA neg <5 vulvo vaginal candidiasis A pos NR neg 772 neg PV
17 29 ill M HW 1w-1m     single VI - mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
18 18 MS UM Stu 1w-6m     single VI - mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
19 18 MS UM Stu 1w-6m     single VI DP - mucoid Moderate HC clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
20 19 MS M Stu 1w-1m     single VI - mucopurulent Moderate Er Sod H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
21 20 MS UM Stu 1w-6m     single VI - mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
22 20 MS M Stu <1w      single VI LAP mucopurulent Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
23 20 HS UM Stu <1w      single dy mucopurulent Moderate Er Sod EX H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
24 32 PS M W <1w      single dy mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis P VDS pos NR neg 435 neg PV
25 20 PS M W <1w      single DP mucopurulent Moderate E TV neg TV neg <5 trichomoniasis A neg NR neg U PV
26 21 D M Stu <1w      single VI dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
27 23 MS M W 1w-1m     single VI mucoid Moderate EX H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
28 25 PS M W 1w-1m     single VI dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
29 27 PS M W 1w-1m     single mucopurulent Moderate Er Sod H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
30 30 ill M W 1w-1m     multiple EMC VI mucopurulent Moderate Sod E PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
31 30 ill M W 1w-1m     multiple EMC DP mucoid Moderate Er E PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PO
32 26 D UM Stu <1w      single VI mucoid Moderate Er H clue cells neg neg neg >5 bacterial vaginosis A neg NR neg neg PV
33 25 PS M W <1w      single dy curdy white Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
34 21 PS UM W 1w-6m     multiple PMC VI DP mucoid Moderate Er H TV neg TV neg >5 trichomoniasis A neg NR neg U PV
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35 21 D M Stu <1w      single VI LAP curdy white Moderate H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
36 22 D UM Stu <1w      single VI curdy white Moderate Er H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
37 28 PS M W 1w-1m     single mucopurulent Moderate Er E PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
38 29 PS M W 1w-1m     single VI dy mucopurulent Moderate E pus cells >30 PC neg neg >5 cervicitis P VDS neg NR neg U PV
39 38 ill D/S CSW <1w      multiple EMC VI dy DP mucopurulent Moderate H TV neg TV neg <5 trichomoniasis P VDS pos NR neg 108 pos PV
40 21 HS UM Stu 1w-6m     multiple PMC VI DP mucoid Profuse Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
41 26 PS M W <1w      single LAP mucoid Moderate Er H TV neg TV neg >5 trichomoniasis A neg NR neg neg PV
42 25 PS M W <1w      single VI dy mucoid Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
43 25 PS M W 1w-1m     single curdy white Moderate H TV neg TV neg <5 trichomoniasis A neg NR neg neg PV
44 24 PS M HW <1w      single VI mucopurulent Moderate E clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
45 34 PS M HW <1w      multiple EMC VI dy mucoid Scanty Er Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis P GUD pos NR neg 689 pos PV
46 29 ill M HW 1w-1m     single VI LAP mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
47 30 PS M HW >6m  single VI DP mucopurulent Moderate EX H TV neg TV neg <5 trichomoniasis P VDS neg NR neg neg PV
48 30 ill M HW >6m  multiple PMC VI curdy white Profuse Sod E PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
49 22 D M Stu 1w-1m     single VI dy mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
50 30 ill M HW <1w      single dy mucopurulent Moderate E clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
51 27 PS M W <1w      single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
52 19 HS UM W 1w-6m     single mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A pos NR neg 383 pos PV
53 25 PS M W 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
54 26 D M Stu <1w      single DP mucopurulent Moderate Er E TV neg TV neg >5 trichomoniasis A neg NR neg neg PV
55 29 PS M HW 1w-1m     single VI LAP mucopurulent Scanty HC negative neg neg neg >5 normal P VDS neg NR neg neg PV
56 26 PS M W <1w      single VI dy mucopurulent Scanty HC negative neg neg neg >5 normal A neg NR neg U PV
57 22 PS UM W 1w-6m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
58 21 ill M W <1w      multiple PMC VI dy mucopurulent Moderate E TV neg TV neg <5 trichomoniasis A neg NR neg U PV
59 26 ill M HW <1w      single curdy white Moderate Sod H PSH neg CA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
60 27 PS M HW 1w-1m     single VI dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
61 25 MS M HW 1w-1m     single VI DP mucoid Moderate H negative neg TV neg <5 trichomoniasis A neg NR neg neg PV
62 23 PS M HW 1w-1m     multiple PMC LAP mucopurulent Moderate Er H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
63 23 PS UM W 1w-6m     single dy mucoid Moderate H TV neg TV pos >5 trichomoniasis A neg NR neg neg PV
64 21 MS M W 1w-1m     single VI dy DP LAP mucopurulent Moderate Er Sod E PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
65 29 PS M HW <1w      single VI mucopurulent Profuse H
clue cells + 
PSH
neg CNA neg >5 BV+VVC A neg NR neg neg PV
66 30 ill M HW 1w-1m     multiple EMC mucoid Scanty Er Sod EX E PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
67 22 ill M W <1w      single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
68 51 ill D/S HW >6m  multiple PMC LAP mucopurulent Moderate E pus cells >30 PC neg pos >5 cervicitis P GUD pos NR neg 698 neg PV
69 28 D M HW 1w-1m     single VI mucoid Scanty H negative neg neg neg <5 normal P VDS neg NR neg neg PV
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70 28 ill M HW 1w-1m     single VI dy mucopurulent Scanty H negative neg neg neg <5 normal P VDS neg NR neg neg PV
71 21 HS M Stu <1w      single LAP mucopurulent Moderate E clue cells neg neg neg <5 bacterial vaginosis A neg NR neg U PV
72 22 PS UM HW <1w      single dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
73 25 PS M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial  vaginosis A neg NR neg neg PV
74 33 ill M W 1w-1m     single dy mucoid Moderate HC clue cells neg neg neg >5 bacterial vaginosis P GUD pos NR neg 665 neg PV
75 29 PS M HW <1w      single VI mucoid Profuse H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
76 30 ill M W 1w-1m     multiple PMC DP mucopurulent Moderate Er Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg pos PO
77 23 MS M HW <1w      single VI dy LAP curdy white Moderate Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
78 21 HS M Stu <1w      single VI dy mucoid Profuse H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
79 29 PS M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
80 30 ill M W 1w-1m     multiple PMC dy curdy white Moderate H clue cells neg neg neg <5 bacterial vaginosis P VDS neg NR neg neg PO
81 22 D M Stu <1w      single VI mucopurulent Moderate Sod EX E PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
82 24 PS M HW 1w-1m     single VI dy DP LAP mucoid Profuse H negative neg TV neg <5 trichomoniasis A neg NR neg neg PV
83 28 PS M W 1w-1m     single mucoid Moderate Er H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
84 28 PS M W 1w-1m     single VI mucoid Moderate H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
85 21 HS M Stu <1w      single VI mucopurulent Moderate E PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
86 22 HS UM W <1w      single VI mucoid Scanty Er Sod H negative neg neg neg <5 normal A neg NR neg neg PV
87 25 PS M HW 1w-1m     single mucoid Moderate H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
88 26 MS M HW 1w-1m     single dy mucoid Moderate H negative neg neg neg <5 normal P VDS neg NR neg neg PV
89 29 ill M HW <1w      multiple PMC VI mucopurulent Moderate E clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg U PV
90 30 ill M HW >6m  single dy curdy white Profuse Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
91 22 PS M HW <1w      single VI mucoid Profuse Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
92 28 ill M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
93 29 ill D/S W 1w-1m     single VI dy DP LAP mucoid Profuse H TV neg TV neg <5 trichomoniasis P GUD neg NR neg pos PV
94 22 PS M HW 1w-1m     single VI dy mucopurulent Moderate E pus cells >30 PC neg neg <5 cervicitis A neg NR neg neg PV
95 21 PS UM W <1w      single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
96 26 D M HW <1w      single VI DP mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
97 25 ill M HW 1w-1m     single dy curdy white Moderate Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
98 25 ill M HW 1w-1m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
99 24 ill M HW <1w      single VI mucopurulent Moderate Er Sod H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
100 31 PS UM W >6m  multiple EMC VI mucopurulent Profuse Er
Strawberry 
cervix
TV neg TV neg <5 trichomoniasis P others neg NR pos pos PV
101 36 ill M HW 1w-1m     single VI LAP mucoid Moderate H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
102 38 ill M HW >6m  single mucoid Moderate H negative neg neg neg <5 normal P VDS neg NR neg neg PV
103 33 PS M HW 1w-1m     single VI dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
104 31 HS M HW <1w      single VI mucoid Moderate H TV neg TV neg <5 trichomoniasis A neg NR neg neg PV
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105 36 ill M HW 1w-1m     single VI dy curdy white Moderate Er Sod H PSH neg CA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
106 34 ill M HW <1w      multiple EMC LAP curdy white Moderate Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A pos NR neg 811 U PV
107 40 ill D/S CSW 1w-1m     multiple EMC DP mucopurulent Moderate E clue cells neg neg neg <5 bacterial vaginosis P VDS neg NR pos pos PA
108 40 ill M HW 1w-1m     single VI dy curdy white Moderate Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P GUD neg NR neg neg PV
109 32 D M HW >6m  single VI mucopurulent Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
110 35 ill M HW >6m  single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
111 36 ill M W 1w-1m     single VI LAP mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
112 32 HS M W 1w-1m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
113 37 ill M HW 1w-6m     single VI dy mucoid Moderate H negative neg neg neg <5 normal P VDS neg NR neg neg PV
114 39 ill M HW <1w      single dy curdy white Moderate Er Sod Ect PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
115 37 MS M W <1w      single curdy white Moderate Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
116 38 ill M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg neg >5 bacterial vaginosis P VDS neg NR neg neg PV
117 40 ill M HW >6m  single VI dy mucoid Moderate H negative neg neg neg >5 normal P VDS neg NR neg neg PV
118 31 HS UM W 1w-1m     multiple EMC dy DP mucopurulent Moderate E pus cells >30 PC neg neg <5 cervicitis P othrs neg R pos U PO
119 35 ill M HW >6m  single VI mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
120 36 ill M HW 1w-1m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
121 39 ill M HW >6m  multiple EMC VI mucopurulent Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
122 37 ill M HW 1w-6m     single VI dy mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
123 38 ill D/S CSW 1w-6m     multiple EMC LAP mucoid Moderate H TV neg TV neg <5 trichomoniasis P GUD neg R pos pos PO
124 32 ill M HW >6m  single DP mucopurulent Moderate E SO >30 PC neg neg >5 cervicitis A neg NR neg neg PV
125 33 ill M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
126 33 ill M HW 1w-1m     single dy DP mucopurulent Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
127 32 D M W <1w      multiple EMC dy curdy white Moderate Er Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
128 36 ill M HW 1w-1m     multiple EMC DP mucopurulent Moderate E SO >30 PC neg neg <5 cervicitis P VDS neg NR neg U PV
129 36 ill D/S HW 1w-1m     single mucoid Profuse Er Ect PSH neg CA neg <5 vulvo vaginal candidiasis P VDS pos NR neg 467 U PV
130 30 ill M W <1w      single VI dy mucoid Scanty Ect clue cells neg neg pos >5 bacterial vaginosis A pos NR neg 542 pos PV
131 37 MS M HW 1w-1m     single VI mucopurulent Scanty H negative neg neg neg <5 normal A neg NR neg neg PV
132 40 ill D/S W 1w-1m     multiple EMC DP mucopurulent Scanty HC negative neg neg neg >5 normal P GUD neg NR neg pos PV
133 32 HS M HW >6m  single dy mucoid Moderate E pus cells >30 PC neg neg <5 cervicitis A neg NR neg neg PV
134 36 ill M W 1w-1m     single VI LAP curdy white Moderate Sod EX H TV + PSH neg
TV + 
CNA
neg >5 TV+VVC P VDS neg NR neg neg PV
135 34 ill M HW 1w-1m     single dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
136 35 ill M HW >6m  single VI dy mucoid Moderate H TV neg TV neg <5 trichomoniasis A neg NR neg U PV
137 38 ill M HW 1w-1m     single VI curdy white Moderate H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
138 35 ill M HW 1w-6m     single VI DP mucoid Scanty H negative neg neg neg >5 normal A neg NR neg neg PV
139 36 ill D/S W 1w-6m     multiple EMC dy mucoid Moderate H TV neg TV neg >5 trichomoniasis P GUD neg NR neg pos PA
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140 39 ill M HW <1w      single VI curdy white Moderate Er Sod H PSH neg CNA neg >5 vulvo vaginal candidiasis A neg NR neg neg PV
141 37 ill M HW >6m  single dy mucopurulent Moderate Er Sod Ect PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
142 38 ill M HW 1w-1m     multiple EMC VI mucopurulent Moderate H clue cells neg neg neg <5 bacterial vaginosis P VDS neg NR neg neg PV
143 32 MS M HW <1w      single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
144 33 ill M HW 1w-1m     single VI mucopurulent Moderate H clue cells neg neg neg >5 bacterial vaginosis A neg NR neg U PV
145 33 ill M W 1w-1m     single VI DP curdy white Scanty Ect negative neg neg neg <5 normal A neg NR neg neg PV
146 32 ill M W 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
147 36 ill M HW 1w-1m     multiple EMC dy DP mucopurulent Profuse H TV neg TV neg >5 trichomoniasis P VDS neg NR neg U PV
148 35 ill M HW <1w      single mucopurulent Moderate H TV neg TV neg >5 trichomoniasis A neg NR neg neg PV
149 31 ill M W <1w      single VI mucoid Scanty Ect negative neg neg neg <5 normal A neg NR neg U PV
150 37 ill M W 1w-1m     single VI LAP mucoid Moderate H TV neg TV neg >5 trichomoniasis A neg NR neg neg PV
151 40 PS M HW >6m  single VI curdy white Profuse Sod H PSH neg CNA neg >5 vulvo vaginal candidiasis P VDS neg NR neg U PV
152 40 ill D/S CSW <1w      multiple EMC VI curdy white Profuse Er Sod EX E PSH neg CNA neg <5 vulvo vaginal candidiasis P GUD pos R pos 623 neg PA
153 31 PS M HW 1w-1m     single VI mucopurulent Scanty Ect negative neg neg neg <5 normal A neg NR neg neg PV
154 31 PS M HW 1w-1m     single dy curdy white Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
155 35 ill M HW 1w-1m     single VI mucoid Moderate EX H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
156 34 PS M W <1w      single dy DP mucopurulent Moderate H TV neg TV neg <5 trichomoniasis A neg NR neg neg PV
157 38 ill M HW 1w-1m     multiple PMC curdy white Scanty H negative neg neg neg <5 normal P VDS neg NR neg neg PV
158 28 ill M HW 1w-1m     single VI mucopurulent Scanty HC negative neg neg neg >5 normal A neg NR neg neg PV
159 38 ill M HW 1w-1m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
160 29 PS M W <1w      single VI dy DP mucoid Moderate Er H TV neg TV neg >5 trichomoniasis A neg NR neg U PV
161 33 ill M W <1w      single DP mucoid Profuse H TV neg TV neg <5 trichomoniasis P GUD pos NR neg 169 pos PV
162 45 ill D/S CSW <1w      multiple PMC mucopurulent Moderate Er Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis P others neg NR neg pos PV
163 53 ill M HW 1w-1m     single mucoid Moderate HC clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
164 56 ill M HW <1w      single VI dy mucoid Moderate HC negative neg neg neg >5 normal P VDS neg NR neg neg PV
165 43 ill M HW <1w      single curdy white Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
166 47 ill M HW 1w-1m     single VI dy LAP mucopurulent Moderate Sod Ect PSH neg CNA neg >5 vulvo vaginal candidiasis P VDS neg NR neg U PV
167 44 ill M W 1w-1m     single mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
168 45 ill M HW <1w      single DP mucopurulent Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
169 30 MS M W <1w      single VI dy mucoid Profuse E pus cells >30 PC neg neg <5 cervicitis A pos NR neg 386 U PV
170 46 PS M HW >6m  single VI dy mucopurulent Moderate Sod EX H PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg U PV
171 49 ill M HW 1w-1m     single LAP mucoid Moderate H TV neg TV neg >5 trichomoniasis P VDS neg NR neg neg PV
172 43 ill M HW 1w-6m     single mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
173 45 ill M HW 1w-6m     single VI mucoid Scanty H negative neg neg neg <5 normal P VDS neg NR neg neg PV
174 42 MS M HW 1w-1m     single VI mucopurulent Profuse H TV neg TV neg >5 trichomoniasis A neg NR neg U PV
175 55 ill M HW 1w-6m     multiple EMC dy curdy white Moderate Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg neg PV
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176 51 ill M HW 1w-6m     single VI mucopurulent Moderate Ect clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg neg PV
177 30 ill M HW 1w-1m     single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
178 41 ill M W 1w-1m     single dy mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg pos PV
179 28 MS UM CSW <1w      multiple PMC VI mucopurulent Profuse Er E
clue cells+ 
PSH
neg CA neg >5 BV+VVC P others pos NR neg 332 pos PO
180 53 ill M HW 1w-1m     single mucopurulent Moderate Er Sod Ect PSH neg CNA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
181 46 ill M HW 1w-1m     single VI mucoid Moderate EX H clue cells neg neg pos >5 bacterial vaginosis P VDS neg NR neg U PV
182 58 ill M HW 1w-1m     multiple PMC VI curdy white Moderate Sod EX H PSH neg CNA neg >5 vulvo vaginal candidiasis A neg NR neg neg PV
183 42 ill D/S HW <1w      single VI DP mucopurulent Moderate Er Sod EX E PSH neg CNA neg >5 vulvo vaginal candidiasis A pos NR neg 551 neg PV
184 46 ill M HW 1w-1m     single VI LAP mucoid Scanty HC negative neg neg neg >5 normal A neg NR neg neg PV
185 43 ill M HW 1w-1m     single dy DP mucoid Moderate H TV neg TV neg <5 trichomoniasis A neg NR neg U PV
186 48 ill M HW 1w-6m     multiple PMC VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
187 45 ill M HW 1w-1m     single dy mucopurulent Moderate H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS neg NR neg U PV
188 44 ill M HW 1w-1m     single mucopurulent Scanty H negative neg neg neg >5 normal A neg NR neg U PV
189 46 ill M HW >6m  single VI mucoid Moderate H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
190 53 ill M HW >6m  single DP mucoid Moderate H TV neg TV neg >5 trichomoniasis P VDS neg NR neg neg PV
191 54 ill D/S HW >6m  multiple PMC dy DP mucopurulent Moderate E SO >30 PC neg neg >5 cervicitis P VDS neg NR neg pos PO
192 55 ill D/S HW >6m  multiple PMC VI curdy white Profuse Sod H PSH neg CA neg >5 vulvo vaginal candidiasis P VDS neg R pos U PV
193 36 ill D/S HW 1w-6m     single VI dy curdy white Profuse Sod H PSH neg CNA neg <5 vulvo vaginal candidiasis P VDS pos NR neg 589 U PV
194 43 ill M HW 1w-1m     single VI mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg U PV
195 42 MS M W 1w-1m     single LAP curdy white Moderate Er Sod H PSH neg CA neg <5 vulvo vaginal candidiasis A neg NR neg neg PV
196 44 ill M W 1w-1m     single VI dy mucoid Profuse EX H TV neg TV neg >5 trichomoniasis A neg NR neg neg PV
197 48 ill D/S HW >6m  multiple EMC DP mucoid Moderate E clue cells neg neg neg >5 bacterial vaginosis P GUD neg R pos pos PO
198 47 ill M HW 1w-1m     single mucoid Scanty H clue cells neg neg pos >5 bacterial vaginosis A neg NR neg neg PV
199 46 ill M HW 1w-6m     single VI dy DP LAP mucopurulent Profuse Er H TV neg TV neg >5 trichomoniasis A neg NR neg U PV
200 45 ill M HW 1w-1m     single VI curdy white Moderate H clue cells neg neg neg >5 bacterial vaginosis P GUD neg NR neg U PV
 KEY TO MASTER SHEET 
 
HS   - High school 
MS   - Middle school 
PS   - Primary school 
D   - Degree 
Ill   - illiterate 
M   - Married 
UM   - Unmarried 
D/S   - Divorced/Separated 
Stu   - Student 
W   - Working 
HW   - Housewife 
CSW   - Commercial Sex Worker 
w   - week 
m   - month 
EMC/PMC  - Extra Marital Contact/ Pre-Marital Contact 
VI   - Vaginal Itching 
dy   - Dysuria 
DP   - Dyspareunia 
LAP   -  Lower Abdominal Pain 
Er   - Erythema 
Sod   - Soddening 
EX   - Excoriation 
H   - Healthy 
E   - Erosion 
Ect   - Ectopy 
HC   - Hypertrophic Cervix 
BV   - Bacterial Vaginosis 
TV   - Trichomonas vaginalis 
VVC   - Vulvo Vaginal Candidiasis 
PSH   - Pseudohyphae 
SO   - Secondary organisms 
CA   - Candida albicans 
CNA   - Candida non albicans 
PC   - Pus cells 
A   -  Absent 
P   - Present 
VDS   - Vaginal discharge syndrome 
GUD   - Genital Ulcer Disease 
NR   - Non reactive 
R   - Reactive 
Neg   - Negative 
Pos   - positive 
PV   - Peno vaginal 
PO   - Peno oral 
PA   - Peno anal 
U   - Unknown 
VCTC  - Voluntary Counseling and Testing Center 
VDRL  - Venereal Disease Research Laboratory 
TPHA  - Treponema Pallidum Haemagglutination  
 
  
PROFORMA 
 
Serial No.                                                               STD OP No. 
 
Name  :                                                                    Age:                  Sex: 
 
Address: 
 
Religion: 
 
Educational Qualification: 
 
Occupation:                                                          Income: 
 
Marital Status: 
 
Duration of marriage: 
 
Occupation: 
 
Address:  
 
PRESENTING COMPLAINTS: 
Genital discharge:  Duration, amount, colour, odour, consistency 
Genital itching 
Genital ulcer  
Fever 
Dysuria 
Dyspareunia 
Lower abdominal pain 
 
MARITAL STATUS: 
 
MENSTRUAL HISTORY: 
 SEXUAL HISTORY: 
Last marital contact /Last contact: 
Extra marital contact: 
Pre-marital contact: 
Previous venereal diseases: 
 
 EXAMINATION 
 
General and systemic examination: 
 
EXAMINATION OF GENITALIA: 
        Vulva: Soddening, fissure, erosion, ulcer, growth 
Inguinal nodes: 
External urethral orifice: 
 
PER VAGINAL EXAMINATION: 
 
SPECULUM EXAMINATION: 
 
GENITAL DISCHARGE: 
Scanty/moderate/ profuse 
Foul smell/ no odour 
Colour:  
Mucoid/mucopurulent/purulent 
Homogenous/floccular/curdy 
 
Skin and mucous membrane: 
Bones and joints: 
 
  
INVESTIGATIONS 
 
Smear for Gram stain: 
       Cervical 
       Vaginal 
 
Wet mount:  
Saline 
 
10% KOH 
 
Culture: 
Gonoco
cci     
Candida 
Trichomonas vaginalis 
 
ELISA for HIV antibody: 
CD4 count: 
VDRL: 
 
 
  
INFORMATION SHEET 
 
 
 We are conducting a study on “COMPARATIVE STUDY ON CLINICO-
EPIDEMIOLOGICAL PROFILE OF SYMPTOMATIC VAGINAL 
DISCHARGE AMONG HIV INFECTED AND NONINFECTED 
WOMEN” attending Rajiv Gandhi Government General Hospital, Chennai and your 
co-operation may be valuable to us. 
 
 The purpose of this study is to identify the etiology, prevalence, demographic 
variables, difference in infectivity pattern and laboratory methods of symptomatic 
vaginal discharge among HIV infected and non-infected women. 
 The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared 
 Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time. Your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
Detailed clinical history including H/O presenting complaints, menstrual history, 
marital history, sexual history, contact history, obstetric history, past H/O sexually 
transmitted  infections will be taken followed by clinical examination. 5 ml blood is 
withdrawn aseptically from the patient. The serum is subjected to ELISA for HIV 
antibody and VDRL if needed. 
 
 
 
 
Signature of Investigator                Signature of  Participant 
 
Date : 
Place : 
 
  
PATIENT CONSENT FORM 
 
Title of the study: “COMPARATIVE STUDY ON CLINICO-EPIDEMIOLOGICAL 
PROFILE OF SYMPTOMATIC VAGINAL DISCHARGE AMONG HIV INFECTED 
AND NONINFECTED WOMEN” 
 
Name of the Participant: 
 
Name of the Principal investigator: Dr.D.GOKILADEVI. 
 
 Name of the Institution: Institute of Venereology, Madras Medical College & Rajiv Gandhi 
Government General Hospital, Chennai-3. 
 
Documentation of the informed consent:  
I  ---------------------- have read the information in this form (or it has been read to me). I was free to 
ask any questions and they have been answered. I am over 18 years of age and exercising my free 
power of choice, hereby consent to be included as a participant in the study. 
1. I have read and understood this consent form and the information provided to me 
2. I have had the consent document explained to me 
3. I have been explained about the nature of the study 
4. My rights and responsibilities have been explained to me by the investigator 
5. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer unusual 
symptoms 
6. I have not participated in any research study at any time 
7. I am aware of the fact that I can opt out of the study at any time without having to give any reason 
and this will not affect my future treatment in this hospital 
8. I hereby give permission to the investigator to release the information obtained from me as a result 
of participation in this study to the sponsors, regulatory authorities, Government agencies and 
institutional ethics committee. I understand that they are publicly presented. 
9. My identity will be kept confidential if my data are publicly presented 
10. I am aware that if I have any question during the study, I should contact at one of the addresses 
listed above. By signing this consent form I attest that the information given in this document has 
been clearly explained to me and apparently understood by me, I will be given a copy of this consent 
document.  
 
Participant initials: 
 
For adult participants: 
 
Name and signature/ thumb impression of the participant (or legal representative if participant 
incompetent) 
_________             __________________                    ----------------- 
Name                        Signature                                      Date 
Name and signature of impartial witness (required for illiterate patients): 
___________           _______________                          _____________ 
Name                          Signature                                       Date 
Address and contact number of the impartial witnesss : 
Name and signature of the investigator or his representative obtaining consent:  
__________________              ____________________               _________ 
Name                                          Signature                                          Date 
Address and contact number of investigator:             
  
  
 
 
PLAGIARISM CERIFICATE 
 
 
 This is to certify that this dissertation work titled “COMPARATIVE STUDY 
ON CLINICO-EPIDEMIOLOGICAL PROFILE OF SYMPTOMATIC VAGINAL 
DISCHARGE AMONG HIV INFECTED AND NONINFECTED WOMEN” of the 
candidate Dr. D.GOKILADEVI with registration Number 201630004 for the award 
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